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CHAPTER I
INTRODUCTION
1. HISTORICAL BACKGROUND
At the beginning of this century proteins were the only molecules
believed to be immunogenic. This concept was based mainly on the work of
the great immunologist Paul Ehrlich. In contrast, lipids were considered to be
poor antigens or even non-immunogenic, because of their small size. This idea
was derived originally from the studies of Karl Landsteiner, who observed
that "...VWien f/ie usua/ mef/io<& o/immumzanon were «jed, jpeci/ïc prore/n-
/ree ,TM0.ïfance.ï o/ am'ma/ or feacferia/ origin, aWiowg/i active 'in vi/ro', o//en
induced no or on/y a s/ign/ an/ioody response." (1). He also observed that
upon mixing with heterologous serum, lipids could stimulate an immune
response in the injected animal. Based on these findings, Landsteiner
developed the theory of the "hapten" for low molecular weight molecules,
which could induce an immune response only after their attachment to high
molecular weight carriers (such as proteins or cells) (1).
This concept was challenged in 1925 by Sachs and Klopstock, who described a
method for the production of antibodies to lecithin (phosphatidylcholine) and
cholesterol (2). Over the next decades these findings have been confirmed and
extended by other authors (3). Nowadays the principle that lipids are
immunogenic is widely accepted and has several practical implications, such
as the development of assays for the measurement of steroids, eicosanoids and
"lipid-like" drugs and the recognition of naturally occurring autoantibodies
against different kinds of lipid molecules.
The development by Wasserman in 1906 of a complement fixation test
to detect "reagin" in the serum of patients suffering from syphilis represents
the beginning of the history of antiphospholipid antibodies (4). It was at first
believed that "reagin" was an antibody directed against the treponema (or one
of its specific antigenic determinants) present in the saline extracts of liver
from fetuses with congenital syphilis. However, in the subsequent years it
became clear that the antigen in the reaction could be replaced by alcoholic
extracts of several normal tissues as well. In 1941 Pangbom demonstrated that
"reagin" was directed against the anionic (read: negatively-charged)
phospholipid extracted from bovine heart (5). This phospholipid has been
named cardiolipin.
At the beginning of the 1950s an important observation was made by
More and Mohr (6), who reported the existence of patients who had detectable
"reagin" in their serum without ever suffering from syphilis. This biologic
false positive test was commonly found in two groups of diseases: viral and
bacterial infections and autoimmune disorders (particularly Systemic Lupus
Erythematosus, SLE). In the former case the biologic false positive test for
syphilis was typically transient, whereas it was chronic in the latter group of
conditions.
In the same period a new inhibitor of coagulation was described. In
1951 Mueller et al. (7) and in 1952 Conley and Hartman (8) reported 3 cases
of a peculiar circulating acquired anticoagulant which prolonged the whole
blood coagulation time and the prothrombin time, was not neutralized upon
addition of normal plasma to the plasma of the patients and was associated
with a chronic false positive test for syphilis. Moreover, in one case the
anticoagulant activity was described to be dependent on the concentration of
the thromboplastin and clinically associated with a history of thrombosis (7).
The immunoglobulin nature of the inhibitor was suspected already in 1955,
when it was observed that the anticoagulant was present both in a female
patient and in her child during the first 6 months of life (9) and this idea was
later confirmed by Loeliger in 1959 (10) and by Yin and Gaston in 1965 (11).
Since the inhibitor was mostly detected in patients with SLE, it was named
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Lupus Anticoagulant (LA) (12). LA antibodies, however, have been detected
in a number of pathologic conditions, such as autoimmune disorders other
than SLE, malignancies, infections, in association with several drugs and also
in the absence of an underlying disease (13). The strong association between
LA antibodies and the false positive test for syphilis was first recognized in
1957, when Laurell and Nilsson (14) observed that LA activity could be
adsorbed from plasma by the cardiolipin portion of the Kahn antigen used in
syphilis tests.
Laboratory resta /or f/ic /denri/jcarion o/a
The identification of LA antibodies in plasma is based on the
prolongation of the coagulation time of a variety of phospholipid-dependent
coagulation tests, such as the kaolin clotting time (15), the activated partial
thromboplastin time, the tissue thromboplastin inhibition test (13) and/or the
dilute Russell viper venom time (16). To exclude that the prolongation of the
clotting time is caused by a deficiency of one or more coagulation factors, it
should be ensured that the prolongation cannot be neutralized upon mixing of
normal plasma with the test plasma. It is also necessary to rule out that the
inhibitor is directed against any coagulation factor. Moreover, a relative
correction of the inhibitory effect should be achieved by addition of lysed
platelets or liposomes containing phosphatidylserine or hexagonal phase (HJT)
phospholipids (see below) (17). These criteria are based on the indications
given by an International Workshop in 1983 (18), which have been recently
revised (19). However, no conclusive agreement has yet been reached on the
methodology for the diagnosis of LA antibodies, illustrated by the great
number of different coagulation tests which have been proposed over the last
decade (20-27).
In 1983, the development of a sensitive solid phase radioimmunoassay
(RIA) for the measurement of anticardiolipin (aCL) antibodies replaced the
semi-quantitative assays which detected "reagin" in serum (28). Two years
later an enzyme-linked immunosorbent assay (ELISA) was proposed for aCL
antibodies, which was shown to be as sensitive as the RIA (29). At variance
with most immunoassays, it was observed that 10% bovine serum solution was
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necessary throughout the ELISA for aCL antibodies, in order to obtain the
best bindings with the lowest background (30).
Soon after the report of this method, it became evident that cardiolipin
could be replaced in the ELISA by other negatively-charged phospholipids as
well, such as phosphatidylserine, phosphatidic acid or phosphatidylinositol
(31-33). On the basis of this finding, assays have been developed that are
based on the adsorption on the ELISA plates of a mixture of negatively-
charged phospholipids. However, the higher specificity and sensitivity of these
assays over the tests in which a single anionic phospholipid is used as an
antigen remain to be demonstrated. In this respect, two International
Workshops have been organized in recent years to standardize the
measurement of aCL antibodies (34, 35). In spite of all these efforts, no
general agreement on the methodology for the detection of aCL antibodies has
yet been achieved and more work will be necessary in the future.
o/anrip/io.sp/io/jpüf an/ifeorf/es
As mentioned above, the association between LA antibodies and
thrombosis was already described in 1951 in the first patient with
antiphospholipid antibodies (7). However, it was not until 1963 that the
association of LA antibodies with thromboembolic complications was clearly
recognized (36). Over the next decades several reports of large series of
patients confirmed the association between antiphospholipid antibodies and a
history of thrombosis of both venous and arterial vessels (37). Association was
found also between the presence of antiphospholipid antibodies and a history
of early recurrent abortions, intra-uterine deaths and intra-uterine growth
retardation (38). In these cases thrombosis of the placental vessels has been
considered the cause of the poor pregnancy outcome (39). Recently,
epidemiological case-control studies performed by our group established the
risk of thrombosis in antiphospholipid antibody-positive patients (40, 41).
Antiphospholipid antibodies are significantly associated also with mild
thrombocytopenia, particularly in patients with SLE (42). Less frequently,
also thrombocytopathia has been described (43). So far, severe
thrombocytopenia, thrombocytopathia and/or hypoprothrombinemia are the
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only known conditions in which antiphospholipid antibody-positive patients
may be at risk of bleeding complications (44).
The association between antiphospholipid antibodies and thrombosis,
recurrent abortions and thrombocytopenia defines a syndrome, named the
"Antiphospholipid Syndrome" (45), which can occur within SLE or as a
separate clinical condition, the so-called "Primary Antiphospholipid
Syndrome" (46). Also livedo reticularis and haemolytic anaemia have been
frequently reported in the Antiphospholipid Syndrome (47).
/?o/e <?ƒ anrip/t05/?Wipüf awrifcorfigj m f/ie p/tf/iögenesw o/ r/iromftewis
The association between antiphospholipid antibodies and thrombosis has
stimulated a great deal of research aimed at defining a pathogenetic role of
these antibodies in the development of thrombosis. Several hypotheses have
been proposed, such as the reduction of the synthesis and/or the release of
prostaclyclin by endothelial cells (48, 49), the interference with the
thrombomodulin/protein C system (50-52), the stimulation of endothelial cell
procoagulant activity (53-55), the activation of platelets (56), the inhibition of
the fibrinolytic system (57), antithrombin III (58) and prekallikrein (59), the
reduction of protein S levels (60) and the stimulation of the thrombin/
antithrombin complex formation (61).
Unfortunately, none of these hypotheses has been confirmed on large numbers
of patients, so that the correlation between antiphospholipid antibodies and a
history of thrombosis has not been unequivocally demonstrated. For this
reason, the question whether these antibodies play any role in the development
of thrombosis still remains to be clarified. In this respect, an answer to this
crucial point might come from the animal models of antiphospholipid
syndrome, which show that the development of antiphospholipid antibodies in
mice is associated with clinical complications similar to those observed in
humans. In particular, it has been described that the immunization of mice
with aCL-positive serum (62), IgG containing antiphospholipid antibodies (63,
64) or monoclonal aCL antibodies (65) is followed by an increased resorption
index of the fetuses (equivalent to recurrent abortions in humans). Similarly,
NZW x BXSB Fl mice spontaneously develop systemic lupus-like disease.
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which is characterized by persistently elevated titer of aCL antibodies,
thrombocytopenia and myocardial infarction (66). So far, these are the first
substantial indications that aCL and/or LA antibodies might, actually, be
involved in the pathogenesis of haemostatic complications.
2. IMMUNOLOGICAL SPECIFICITY OF ANTIPHOSPHOLIPID
ANTIBODIES
As already mentioned, the immunological specificity of "reagin" was
elucidated in 1941 by Pangbom (5), who demonstrated that the antibody was
directed against cardiolipin, the negatively-charged phospholipid present
together with cholesterol and lecithin (phosphatidylcholine) in the VDRL
(Venereal Disease Research Laboratory) antigen.
An important development in the field of the immunology of reagin was made
by Cooper et al. (67), who purified from the serum of a patient suffering
from chronic lymphocytic leukemia a monoclonal IgM, which expressed a
very high VDRL titer and was able to precipitate both cardiolipin and
phosphatidylcholine. Precipitin lines were observed also with
phosphatidylserine, phosphatidic acid, phosphatidylethanolamine and
sphingomyelin. For the first time the concept of the immunological cross-
reactivity of antiphospholipid antibodies was introduced. Interestingly,
phosphatidylethanolamine, sphingomyelin and phosphatidylcholine are not
negatively-charged but zwitterionic (read: neutral) phospholipids.
With the subsequent development of solid phase immunoassays (28, 29) it has
been widely confirmed that aCL antibodies positive sera react with all the
anionic phospholipids, whereas zwitterionic phospholipids are not recognized
by aCL antibodies. There are, however, a few exceptions to this
immunological behaviour, such as the observation of antiphosphatidyl-
ethanolamine antibodies reported by Staub et al. (68) and, as afore mentioned,
Cooper et al. (67).
In some cases the wide immunological cross-reactivity of aCL
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antibodies has been extended to DNA, since some (monoclonal) anti-DNA
antibodies were shown to bind also to cardiolipin (31, 69). This cross-
reactivity has been explained on the basis of the similarity between the polar
head groups of the phospholipids and the phosphodiester groups on the
polynucleotide backbone of DNA (31). However, in most cases anti-DNA and
aCL antibodies comprise different specificities (70, 71).
The hypothesis that LA might belong to the family of antiphospholipid
antibodies originated from the frequent association with aCL (or "reagin")
antibodies and from the prolongation of the phospholipid-dependent
coagulation tests. However, it was not until 1980 that the antiphospholipid
nature of LA antibodies was described, when a monoclonal IgM with LA
activity was purified from the plasma of a patient suffering from
Waldenstróm's macroglobulinemia (72). By double immunodiffusion the
isolated IgM was shown to form a precipitin line with several negatively-
charged phospholipids, such as phosphatidylserine, phosphatidic acid and
phosphatidylinositol. Also its anticoagulant mechanism was elegantly
elucidated: the IgM inhibited the calcium-dependent binding of coagulation
factors X and prothrombin to the negatively-charged phospholipid
procoagulant surface (72). The same group later confirmed and extended
these findings to antibodies of the IgG isotype (73). They developed a method
for the purification of aCL antibodies based on serum (or plasma) adsorption
by liposomes containing cardiolipin and subsequent elution of the antibodies
from the lipids. aCL antibodies isolated via this procedure were shown to bind
not only to cardiolipin, but to a variety of negatively-charged phospholipids
and to express LA activity as well, since they were able to prolong the
coagulation time of phospholipid-dependent coagulation tests (73). Again, IgG
aCL antibodies were shown to compete with coagulation factors X and
prothrombin for the calcium-dependent binding to the procoagulant
phospholipid surface (73).
On the basis of these findings it was suggested that LA and aCL
antibodies were closely related or even identical. The observation that these
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two antibodies were concurrently present in approximately 75% of the
patients contributed to strengthen this hypothesis (42).
LA am/ aCL anriftodïes comprise djjj'erenf //nmMno/og/ca/ 5/?ec(/jcj7/ej
In 1988 two groups of investigators independently reported that in
most cases aCL could be separated from LA antibodies (74, 75). They used
elegant methods for the purification of antiphospholipid antibodies, based on
the immobilization of the anionic phospholipid (phosphatidylserine or
cardiolipin) over columns of polyacrylamide gel (75) or polystyrene/
siliconized sand (74), respectively. The chromatography of LA and aCL
antibodies positive plasmas over these columns resulted in the separation of
the antibodies into two peaks, one containing LA, the other aCL antibodies.
The evaluation of the immunological properties of the two separated
antibodies showed that aCL antibodies were able to bind to several anionic
phospholipids in the immunoassays but did not express anticoagulant activity
in vitro, whereas LA antibodies, in spite of the ability to prolong the
phospholipid-dependent coagulation reactions, did not bind to anionic
phospholipids in the immunoassays (76). Moreover, in some patients aCL and
LA antibodies belong to different immunoglobulin isotypes (76). Henceforth,
the concept that aCL and LA antibodies comprise separate immunological
specificities has been confirmed and widely accepted.
In the recent years the possibility that LA antibodies may be directed
against unusual antigenic targets has been object of ample investigation. In this
respect, it has been shown that the anticoagulant activity of LA antibodies can
be neutralized in plasma by phosphatidylethanolamine, a new/ra/ phospholipid,
when it is used in the hexagonal (HJJ) phase (77). In contrast, the same lipid in
the lamellar phase does not influence the expression of the anticoagulant
activity of LA antibodies (77).
Most of the neutral and negatively-charged phospholipids commonly adopt the
bilayer structure in aqueous solutions. However, it has been observed that
phosphatidylethanolamine, as well as cardiolipin and phosphatidic acid, may
also adopt hexagonal structures and non-bilayer intermediates under
physiological conditions (78).
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Hexagonal (HJJ) phosphatidylethanolamine consists of hexagonally packed
cylinders of lipid surrounding central aqueous channels toward which the
polar head groups are oriented. In this way, a peculiar lipid surface is formed,
that has been suggested to be specifically recognized by LA antibodies (79).
In fact, human hybridoma LA IgM have been shown to distinguish between
the lamellar and hexagonal (HJJ) phase of the same lipid (79). Although this is
a very attractive hypothesis, there is still little evidence of direct binding of
LA antibodies to hexagonal phase (HJJ) phosphatidylethanolamine, since the
experiments have not been performed in systems with purified
immunoglobulins and purified coagulation factors, but always in plasma (17,
79). Moreover, a possible interaction of hexagonal phase (HJJ )
phosphatidylethanolamine with aCL antibodies has not yet been evaluated.
The frequent observation of reduced levels of prothrombin in the
plasma of LA-positive patients led several authors to investigate whether LA
antibodies could interact also with prothrombin. In this respect, it has been
shown that non-neutralizing anti-prothrombin antibodies are present in a
consistent percentage of LA-positive patients with both reduced and normal
levels of prothrombin (44).
Recently, it has been demonstrated that LA-associated hypoprothrombinemia
derives from the presence of prothrombin-antiprothrombin complexes, which
are quickly scavenged from the circulation (80, 81). Based on the adsorption
of LA antibodies from plasma by insolubilized prothrombin and the
subsequent elution of the anticoagulant activity from the complex. Fleck and
coworkers (81) suggested that LA antibodies may recognize unknown
antigenic epitope(s) on prothrombin, thus implying that the immunological
cr.oss-reactivity of LA antibodies extends beyond phospholipids.
and ce// me/nbra/ie
Anionic phospholipids are essential constituents of the plasma
membranes of cells and they are usually located in the cytoplasmic leaflet.
Thus, they are not available for antiphospholipid antibodies. However, under
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physiological conditions this asymmetric distribution can be lost, resulting in
exposure of negatively-charged phospholipids on the outer membrane surface
(82). For platelets this phenomenon occurs upon activation by different
agonists and is accompanied by shedding of microvesicles (82). Activated
platelets and platelet-derived microvesicles provide a catalytic surface for the
interaction of coagulation factors and, in this way, acquire procoagulant
properties (82). Also endothelial cells (83, 84) and monocytes (85, 86) may
become procoagulant, following stimulation with different kinds of agents.
Platelets, endothelial cells, monocytes and also lymphocytes are cells
which play a pivotal role in the processes of haemostasis, thrombosis and
inflammation. Thus, the interaction between antiphospholipid antibodies and
the plasma membrane of these cells has been widely investigated, since it
might result in the modulation of the cellular pro- and anticoagulant
properties.
Binding of antiphospholipid antibodies to platelet membrane has been reported
by some authors to occur with freeze-thawed (87), activated (88) and even
resting (33, 89) platelets. In contrast, other authors failed to show any binding
to the membrane of platelets (72). Anti-endothelial cell antibodies have been
frequently reported in association with antiphospholipid antibodies mostly in
patients with SLE, but the identity between these two types of antibodies has
never been demonstrated (90, 91). Finally, the interaction of antiphospholipid
antibodies with monocyte procoagulant activity (92), their binding to
lymphocytes (93) or their elution from red blood cell membrane in patients
with autoimmune haemolytic anaemia (94) have also been sporadically
reported in the literature.
3. "COFACTORS" FOR THE EXPRESSION OF LA ANTIBODIES
The first report of the existence of a "cofactor" for the expression of
LA antibodies was made already in 1959 by Loeliger (10). In fact, this author
observed that the coagulation times of a mixture of normal with patient's
plasma were more prolonged than that of the patient's own plasma.
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Characteristically, a low level of prothrombin was also found in the plasma of
the patient. Experiments on adsorption of patient's plasma with BaSC>4 led this
author to suggest that prothrombin might be the "cofactor" of LA antibodies
(10).
More work on the "cofactor"of LA antibodies was made in 1965 by Yin
and Gaston (11). In contrast with Loeliger's findings, these investigators
identified the "cofactor" activity in the gammaglobulin fraction. The molecule
showed some peculiarities: it had a sedimentation coefficient of 6.6 Svedberg
units, could be isolated from both normal and parien/'s plasma and was neither
heat-stable nor adsorbed by BaSC>4 (11).
In 1974 another group studied the properties of the "cofactor" of LA
antibodies (95). The "cofactor" activity could be detected both in plasma and
in serum of normal subjects, had an apparent molecular weight of 200 kD,
was sparingly adsorbed by A1(OH)3 or BaSO^ stable at room temperature but
largely destroyed by heating at 56°C for 30 min. These properties were
different from those of both prothrombin and a gammaglobulin.
Finally, in 1978 Exner et al. (15) suggested that the "cofactor" of LA
antibodies might be a mere artefact, due to the presence in some LA-positive
plasmas of residual platelets or platelet "dust". This extra procoagulant surface
was diluted upon mixing of the patient's plasma with normal plasma, thus
explaining why the coagulation times of the plasma mixture were longer than
those of the patient's own plasma.
Over the years all the authors who developed new coagulation tests for
the diagnosis of LA antibodies reported about the existence of a "cofactor" of
LA antibodies. However, probably due to the controversial findings, no
further attempts directed towards identification and characterization of the
"cofactor" of LA antibodies were made.
4. AIM OF THE STUDY
The aim of the present study was to investigate the role of protein
"cofactors" for the expression of the immunological activity of
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antiphospholipid antibodies. In particular:
- Chapter II evaluates the role of human prothrombin for the expression of
LA activity in plasma;
- Chapter III describes the characterization of a protein in human (bovine)
plasma (serum), which is necessary for the binding of aCL antibodies to
cardiolipin and other negatively-charged phospholipids and its identification as
f$2-Glycoprotein I;
- Chapter IV evaluates the role of 62-Glycoprotein I in the expression of the
anticoagulant activity of aCL antibodies;
- Chapter V reports on the interaction of LA and aCL antibodies with the
procoagulant activity of both platelets and platelet-derived microvesicles;
- Chapter VI gives a general discussion of the results.
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CHAPTER II
LUPUS ANTICOAGULANT IgG's (LA) ARE NOT DIRECTED TO
PHOSPHOLIPIDS ONLY, BUT TO A COMPLEX OF LIPID-
BOUND HUMAN PROTHROMBIN
based on:
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SUMMARY
Plasmas from 16 patients that were found to be positive for both anti-
cardiolipin (aCL) and lupus anticoagulant (LA) antibodies were incubated
with liposomes that contained anionic phospholipids. In 11 of these plasmas,
aCL antibodies could be co-sedimented with the liposomes in a dose-dependent
manner, whereas LA activity of the remaining supernatant was unaffected. LA
activity of purified total IgG from 6 patients was measured in three different
coagulation tests, using normal plasmas from different species. Prolongation
of the aPTT, KCT and dRVV clotting times was observed only with normal
plasma from human origin, not with bovine, rat or sheep plasma.
Highly purified coagulation factors Xa, Va and prothrombin, both of
human and bovine origin, were used to establish for two patient IgG's the
effect of LA antibodies on the rate of thrombin formation in the presence and
absence of lipid vesicles composed of 20 mole% phosphatidylserine and 80
mole% phosphatidylcholine. A strong and dose dependent inhibition by LA
antibodies was observed only when human prothrombin was used as substrate
in the prothrombinase complex in the presence of lipids. No inhibition was
found when bovine prothrombin was used as substrate. The inhibitory effect
observed in the presence of human prothrombin was independent of the
source of factors Xa and Va, and was not found in the absence of lipid.
Binding studies show that LA antibodies only associate with a lipid surface,
provided that human prothrombin and calcium ions are present. These data
indicate that LA antibodies are not directed to phospholipids alone, but
presumably recognize an epitope which becomes exposed upon Ca -mediated
binding of human prothrombin to phospholipids.
INTRODUCTION
A characteristic feature of plasma from patients with the Anti-
Phospholipid Syndrome (APS) is the occurrence of antibodies to anionic
phospholipids (anticardiolipin, aCL, antibodies) frequently in combination
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with so-called lupus anticoagulant (LA) antibodies (1). aCL antibodies are
usually detected by solid phase immunoassays as described by Loizou et al.
(2), whereas LA antibodies are measured as an activity which prolongs lipid-
dependent coagulation reactions assayed by standard techniques such as aPTT,
KCT and dRVV (3). Since it is generally assumed that in these assays the
prolonged clotting time is due to lipid-directed antibodies that compete for the
binding of coagulation factors to the phospholipid surface, it has been
suggested that both antibodies may be identical (4, 5).
However, several studies have indicated that at least in a number of
patients aCL can be separated from LA antibodies (6, 7). Recently, it was
found that interaction of aCL antibodies with cardiolipin as well as other
anionic phospholipids requires the presence of beta2-glycoprotein I (B2-GPI)
(8, 9 and Chapter III of this thesis). This protein, which is present in normal
plasma, was shown to have anticoagulant properties (10, 11). During our
studies on the role of 82-GPI in promoting the binding of aCL antibodies to
negatively charged phospholipids, we noticed that selective removal of aCL
antibodies from plasma of patients with both LA and aCL antibodies did not
affect the LA activity of these plasmas. Furthermore, in their studies on
separated aCL and LA antibodies, McNeil et al. found that antibodies
responsible for LA activity do not bind to isolated phospholipids in solid phase
immunoassays, and conversely that aCL antibodies do not possess LA activity
as measured by aPTT and KCT (7).
The present study was undertaken to elucidate the mechanism by which
LA antibodies cause prolongation of the clotting time of lipid-dependent
coagulation reactions. We have used highly purified human and bovine
coagulation factors to study the effect of LA IgG from two different patients
on the rate of thrombin formation. Evidence is presented that LA antibodies
are not directed to phospholipids alone, but recognize an epitope on lipid-
bound prothrombin.
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MATERIALS AND METHODS
Initially, we studied 16 patients, who were found to be seropositive for aCL
and LA antibodies as determined by standard solid phase immunoassay (2) and
aPTT or d R W (3). Of the patients whose LA activity was distinct from aCL
(see Fig. 1), two men (aged 52 and 39) were selected for further investigation
of the mode of action of LA antibodies. One of them showed symptoms of
superficial thrombophlebitis, while the other had suffered from recurrent
peripheral thrombosis. None of them fulfilled criteria for diagnosis of SLE
(12).
Separation o/L-4/rom aCL
Liposomes, used to investigate whether aCL antibodies could be separated
from LA antibodies, were composed of a mixture of cardiolipin,
phosphatidylcholine and cholesterol in a molar ratio of 2.5:10:4, respectively.
When cardiolipin in these liposomes was replaced by phosphatidylserine, twice
the amount of the latter Iipid was used. All lipids were from Sigma, St Louis,
MO. Liposomes were added to patient plasma and after incubation for 30 min
at 37 °C they were removed by centrifugation for 10 min at 12,000 x g. The
liposome-free supernatant was analysed for aCL antibodies, essentially
following the procedure of Loizou et al. (2). LA activity was measured by
aPTT (3), using a mixture of 1 vol supernatant and 2 vol normal plasma. No
difference in aPTT clotting time was found between the supernatant of normal
plasma treated with liposomes and normal plasma treated with an equal
volume of Tris buffer. This indicates that traces of Iipid material left in the
patient plasma after liposome extraction did not interfere with the aPTT. The
aPTT was performed using Thrombofax (Ortho diagnostics) according to the
manufacturers' instructions. KCT was carried out as described by Exner et al.
(13) and dRW as described by Thiagarajan et al. (14).
IgG was isolated from patient plasma by affinity chromatography using
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protein A-sepharose CL 4B (Pharmacia Fine, Uppsala, Sweden). These
preparations were found to retain both aCL and LA activity. ,
o/profAromtomue activity
For measuring prothrombinase activity, highly purified coagulation factors of
human and bovine origin were used. Coagulation factors Xa, Va and
prothrombin were purified from bovine plasma as described by Rosing et al.
(15) and from human plasma as described by Tans et al. (16). As lipid source
in the assay, we have used unilamellar vesicles, prepared by sonication in
"tris"-buffered saline (TBS; 0.05 mol/1 tris, 0.1 mol/1 NaCl, pH 7.4) of a
mixture composed of 20 mole% phosphatidylserine and 80 mole%
phosphatidylcholine. Prothrombinase activity was measured essentially
according to ref. 17, with minor modifications. The prothrombinase assay was
performed in TBS (pH 7.4) containing 0.5 mg/ml human serum albumin
(essentially fatty acid-free, Sigma, St Louis) as follows: 125 |il prothrombin
(4 nmol/1) was preincubated for 5 min at 37 °C with 250 |ji lipid vesicles (1.2
|imol/l) in the presence of 25 jil 60 mmol/1 CaC^ and 50 |il normal or patient
IgG (concentration as indicated in the text). Thrombin formation was initiated
by addition of 50 |il of a mixture of factor Xa and Va (1.0 and 2.0 nmol/1,
respectively). In case the prothrombinase activity was measured in the absence
of phospholipid, the concentrations of factor Xa and Va were chosen 10-fold
higher. At different time intervals, 25 pJ aliquots were transferred from the
prothrombinase mixture to a cuvette containing 1.0 ml TBS/EDTA (2.0
mmol/1 EDTA), pH 7.4, to stop the reaction. Thrombin-specific chromogenic
substrate S2238 (Kabi diagnostics, Stockholm) was added at a final
concentration of 250 nmol/1 and from the change in absorbance at 405 nm the
amount of thrombin was calculated using a calibration curve made with
known amounts of active site titrated thrombin (15).
To investigate whether human prothrombin was required for the binding of
LA antibodies to a procoagulant surface, red blood cell (RBC) ghosts,
prepared according to Bevers et al. (18) were used. RBC ghosts were chosen
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because they provide a readily sedimentable procoagulant surface. Briefly: 10
Hi LA IgG (1 mg/ml final concentration) were mixed with 150 u.1 RBC ghosts
at various concentrations and 40 |il human prothrombin (final concentration 2
Hmol/1) in Hepes buffer containing 3 mmol/1 CaC^. After 15 min incubation
at 37°C the mixture was centrifuged at 12,000 x g for 5 min and the
supernatants were analyzed for the residual LA activity as well as
prothrombin.
Prothrombin was measured after its conversion to thrombin by Echis
carinatus venom, using the thrombin-specific chromogenic substrate S2238.
Under the conditions described, up to 40% of the prothrombin binds to the
RBC ghosts at the highest ghost concentration used. This value was not
affected when either LA or non-specific IgG was present. Therefore, the
supernatants of the binding experiments could be used subsequently as a
source of prothrombin in the prothrombinase assay, taking care that the
amount of prothrombin in the assay is adjusted to the same final concentration
(2 nmol/m) by addition of "exogenous" prothrombin.
LA activity was evaluated by its inhibitory activity in the prothrombinase
assay. This assay was performed essentially as described above. Briefly: 60 ul
supernatant of each binding experiment (adjusted to the same prothrombin
concentration: see above) were incubated with 10 (J.1 3 (imol/1 PS/PC vesicles
(molar ratio 20/80) in the presence of 3 mmol/1 CaC^. After 10 min at 37 °C
10 nl bovine Xa and Va (1 and 2 nmol/1 final concentration, respectively)
were added to start prothrombin conversion. After 2 min, 25 p.1 of the
incubation mixture were transferred to a cuvette containing 1 ml TBS/EDTA
(2 mmol/1 EDTA), pH 7.4, to stop the reaction. S2238 was added at a final
concentration of 250 nmol/1 and from the change in absorbance at 405 nm the
amount of thrombin was calculated using a calibration curve made with
known amounts of active site titrated thrombin.
32
RESULTS AND DISCUSSION
Plasmas from 16 patients with both LA and aCL activity were incubated
with liposomes containing either cardiolipin or phosphatidylserine. After
removal of the liposomes by centrifugation, the remaining plasma
supernatants were tested for aCL and LA activity. In 11 out of these 16
plasmas, it appeared possible to reduce the aCL titer without affecting the LA
activity. In the remaining 5 patient plasmas, LA activity co-sedimented with
aCL antibodies and liposomes. As explained in Chapter IV, these plasmas
contain aCL antibodies which express an anticoagulant activity that is
dependent on l^-Glycoprotein I (62-GPI). In the present study, we have
focused on LA antibodies from which aCL antibodies can be separated by
liposome extraction. Fig. 1 shows data from a representative experiment in
which the loss of aCL antibodies was a function of the amount of liposomes
added to the plasma. Essentially the same results were obtained when
cardiolipin-containing liposomes were substituted by other commercially
available phospholipid preparations used for standard coagulation assays
(Actin from Dade and Thrombofax from Ortho diagnostics). Furthermore, it
is obvious that in this group of patients LA antibodies are unable to bind to a
lipid surface which contains anionic phospholipids. These findings are
consistent with earlier reports by Exner et al. (6) and McNeil et al.(7)
demonstrating that aCL and LA antibodies comprise separate antibody
subgroups.
In order to test the possibility that binding of LA antibodies to anionic
phospholipid would require calcium ions, we incubated affinity-purified total
IgG with the same phospholipid preparations either in the presence or absence
of calcium. None of the phospholipid preparations were able to reduce the LA
content of the total IgG, irrespective of the presence of calcium ions. This
observation makes it unlikely that prolongation of the clotting time by LA
antibodies is caused by a calcium-dependent interaction of LA antibodies to
the lipid surface.
These results led us to investigate whether a protein-cofactor might be
required for interaction of LA antibodies with phospholipid.
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Table I. LA activities of total IgG's in various coagulation assays using human
and bovine plasma
Sample
Tris/NaCl
N-IgG
Pat. 1
Pat. 2
Pat. 3
Pat. 4
Pat. 5
Pat. 6
aPTT(s)
Human
59.5
60.1
74.2
96.4
72.0
81.1
92.2
117.0
Bovine
75.9
78.2
77.3
79.6
76.0
76.2
78.0
77.4
Kcrrs)
Human
105.6
112.0
142.0
154.5
134.5
176.9
184.2
270.4
Bovine
108.0
105.4
110.2
113.0
109.4
106.0
110.1
108.5
dRVVT (i
Human
58.7
59.8
74.2
71.1
62.7
87.5
86.7
123.4
Bovine
35.8
35.2
35.4
35.5
37.5
36.0
36.1
35.0
To this end, LA activity of purified total IgG from 6 out of the 11 previously
selected patients was measured in three different coagulation assays, an aPTT,
a KCT and a dRVV using either normal human plasma or bovine plasma. In
all three assays and with all patient IgG's, prolongation of the clotting time
was found only when human plasma was used (Table I). Lack of inhibition
was also found with sheep or rat plasma (data not shown). Similar
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observations have been reported earlier by Clyne in studies in which patient
plasmas were mixed with animal plasmas (19). It was also excluded that lack
of inhibition was related to different levels of coagulation factors in the
animal plasmas (19). Since it is highly unlikely that the conformation of the
lipid surface will depend on the plasma source, these results further confirm
that LA antibodies do not directly bind to lipid. On the contrary, these data
strongly suggest that a species-specific plasma component is required for
expressing LA activity.
Of the three different clotting assays described in Table I, the dRVV is
critically dependent on the conversion of prothrombin to thrombin by factors
Xa and Va (3). We therefore investigated for two patients the effect of LA
antibodies on the prothrombinase reaction using highly purified coagulation
factors of both human and bovine origin. First we confirmed that aCL
antibodies, purified as described by Galli et al. (9), have no effect on the
prothrombinase assay. Purified aCL antibodies, free of LA activity as
determined by dRVV, did not inhibit the prothrombinase assay up to
concentrations of 150 ng/ml. Thus, no further attempts were made to obtain
an aCL antibody-free LA preparation to perform the experiments described
below. Total patient IgG showed a dose-dependent inhibition of the
prothrombinase activity in a system with human coagulation factors Xa, Va
and prothrombin in the presence of lipid vesicles composed of 20 mole%
phosphatidylserine and 80 mole% phosphatidylcholine (Fig. 2A). In contrast,
no inhibitory effect was observed when human prothrombin was replaced by
bovine prothrombin. When the human coagulation factors Xa and Va were
substituted by the corresponding bovine factors, the same result was obtained,
i.e. inhibition was only observed with human prothrombin, not with bovine
prothrombin (Fig. 2B). Also, purified total IgG from another patient was
found to inhibit the prothrombinase assay only when human prothrombin was
used as a substrate. It should be emphasized that when phospholipid was
omitted from the prothrombinase assay, no appreciable inhibition by total IgG
was observed, irrespective of whether human or bovine prothrombin was used
as a substrate.
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In summary, the results presented in this paper clearly indicate that
expression of LA activity requires the presence of both anionic phospholipids
and /in/nan prothrombin. Apparently, these antibodies are not directed to
phospholipids alone. Also the possibility that the antibodies interact with a
putative lipid structure that is modified by binding of prothrombin is
extremely unlikely, because such a modification would be expected to be
independent of the species-origin of prothrombin. Two alternatives remain: (i)
LA antibodies recognize an epitope which becomes exposed upon Ca-mediated
binding of prothrombin to anionic phospholipid, or (ii) LA antibodies can
bind an epitope on prothrombin which prevents the latter from interacting
with phospholipids.
To investigate which of these two possibilities could account for the
inhibitory effect of LA antibodies, we performed direct binding experiments
in which LA and prothrombin were incubated with a readily sedimentable
procoagulant phospholipid surface, i.e. red blood cell (RBC) ghosts. Under
the conditions described in the method section, up to 40% of the prothrombin
binds to the RBC ghosts at the highest ghost concentration used. This value
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was not affected when either LA or non-specific IgG was present. Thus, the
binding of prothrombin to the lipid surface is not prevented by LA IgG. LA
activity was evaluated by its inhibitory activity in the prothrombinase assay.
Fig. 3 shows the LA activity of the supernatant as a function of the
concentration of RBC ghosts. When LA was incubated with RBC ghosts in the
absence of prothrombin, LA activity of the supernatant remained unchanged.
However, when the incubation of the RBC ghosts was carried out in the
presence of human prothrombin, a progressive loss of LA activity of the
supernatant was observed when the antibodies were incubated with increasing
concentrations of RBC ghosts. It has to be emphasized that this decrease was
only found when CaC^ was present during the binding step. From these data
we conclude that LA antibodies recognize the complex of phospholipid-bound
human prothrombin, in this way producing prolongation of phospholipid-
dependent coagulation tests.
In the past decades, a possible involvement of prothrombin in
expression of LA activity has been surmized by different laboratories.
Already in 1959, Loeliger proposed that prothrombin should be considered a
cofactor for LA antibodies (20). Indeed, a remarkably high prevalence of
associated anti-prothrombin antibodies has been reported for LA-positive
plasmas, frequently associated with low levels of prothrombin in these plasmas
(21,22). Fleck and coworkers (22) suggested that these antibodies exhibit
1 2 3
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polyreactivity including to epitopes on prothrombin. A reduced level of
prothrombin (approximately 60%) was also found in the plasma of the patient
whose LA effect on the prothrombinase assay is shown in Fig. 2. However, the
prothrombin concentration in the plasma of the other patient, whose LA
antibodies showed essentially the same effect on the prothrombinase assay, was
found to be normal. At present, it is difficult to ascertain to what extent
reduced levels of prothrombin in these patients arise from antibodies directed
to lipid-bound prothrombin, or to prothrombin not associated to lipid. Our
results are not necessarily in contradiction to those of Rivard and coworkers
(23), who concluded that LA-cofactor activity of normal plasma was
dissimilar from prothrombin. They studied a patient with a classical SLE,
whose plasma was LA positive, but it is unclear whether this plasma also
contained separable or non-separable aCL activity. Moreover, their results
could also be explained by a bypass effect caused by platelet contamination in
the plasmas, as discussed by Exner and Triplett (3).
If LA antibodies are indeed directed to a prothrombin/phospholipid
complex, one could consider prothrombin to be the counterpart of 82-GPI in
the binding of aCL antibodies to phospholipid (8, 9 and Chapter III of this
thesis). In this respect it is tempting to speculate that the underlying
mechanism of antiphospholipid syndrome is an increased expression of
procoagulant lipid surfaces, e.g. caused by complement-induced endothelial
cell damage or platelet activation and microparticle formation (24, 25). The
immune response does not necessarily have to be directed to anionic
phospholipids, but could be focused on plasma proteins which bind to these
lipids thus exposing cryptic epitopes. Both prothrombin and 62-GPI are likely
candidates, because they are abundant in plasma (approx. 2.5 nmol/1 and 4
|imol/l, respectively) and have a relatively high affinity for anionic
phospholipids. This hypothesis also offers a possible explanation for the
frequently observed concurrent expression of LA and aCL antibodies in the
antiphospholipid syndrome. Caution should be exercised, however, in making
generalizations, because there are patients in whose plasmas aCL and LA
antibodies cannot be separated into two different immunoglobulin fractions.
The study of these antibodies in systems using purified coagulation factors and
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well defined phospholipids may contribute to a better understanding of their
mode of action.
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CHAPTER III
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SUMMARY
The binding of affinity-purified anticardiolipin (aCL) antibodies to
liposomes that contained cardiolipin or phosphatidylserine was investigated.
aCL antibodies bound to these liposomes only in the presence of plasma or
serum, which indicated a requirement of a plasma component. This
component -referred to as aCL-cofactor- was purified; its activity to support
aCL antibodies binding to liposomes that contained cardiolipin was not
destroyed by heat (10 min at 90 °C) but was greatly diminished on incubation
with trypsin. aCL-cofactor bound liposomes that contained negatively-charged
phospholipids but had no affinity for liposomes that contained neutral
phospholipid (eg, phosphatidylcholine); this binding was independent of
calcium ions. aCL-cofactor was essential for aCL antibodies to bind to
liposomes that contained cardiolipin and phosphatidylserine and, when coated
on a microtiter plate in the absence of any phospholipid, aCL-cofactor was an
apparent antigen for aCL antibodies in an enzyme-linked immunosorbent
assay. aCL-cofactor is a single chain polypeptide with an apparent molecular
weight of 50 kD (non-reduced), which increases to 70 kD upon reduction, and
its properties closely resemble those of B2-glycoprotein I (apolipoprotein H).
INTRODUCTION
Anticardiolipin (aCL) and lupus anticoagulant (LA) antibodies are
closely related autoantibodies, which may be found in the plasma of patients
with Systemic Lupus Erythematosus (SLE), other immunological, neoplastic
or infective disorders and apparently normal people with no evidence of
underlying disease (1). Some 30% of people who have these antibodies suffer
from arterial or venous thrombosis, thrombocytopenia and recurrent
abortions (1).
aCL and LA antibodies are detected because they react with negatively-
charged phospholipids (eg, phosphatidic acid, cardiolipin, phosphatidylserine
and phosphatidylinositol) in immunoassays (2,3) and because they prolong
phospholipid-dependent clotting tests "in vitro" (4).
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In 1959, Loeliger observed that some plasma samples showed enhanced
LA activity when mixed with normal plasma (5); the concept of LA cofactor
was introduced and prothrombin was suggested to represent this cofactor (5).
In 1965, LA cofactor was localized in the gammaglobulin fraction of both
normal and LA positive plasma (6). Rivard et al. (7) showed that LA cofactor
was neither prothrombin nor a gammaglobulin but a different molecule with
an apparent molecular weight of 200 kD (7) - although it has also been
suggested that the cofactor is a laboratory artifact (8). We have purified and
characterized a protein, termed aCL-cofactor, which is found in normal
plasma and is required for the expression of aCL activity.
MATERIALS AND METHODS
We studied plasma from 2 men found to be seropositive for both aCL and LA
antibodies on routine investigation by enzyme-linked immunoassays (ELISAs).
One patient, aged 39, had had repeated peripheral thrombosis; the other, aged
51, had had recurrent thrombosis of cerebral and renal arterioles. Neither had
any other feature to suggest a diagnosis of SLE (9).
aCL antibodies were purified by a modification of the method described by
Pengo et al. (10). Briefly, a mixture of cardiolipin, phosphatidylcholine and
cholesterol (molar ratio 2.5:10:4; all from Sigma, St. Louis, MO, USA) in
ethanol was dried under a stream of nitrogen. The lipids were resuspended
directly in the plasma of the patients to a final cardiolipin concentration of 3
mg/ml. After incubation at 37 °C for 1 h, the mixture was diluted 1:4 in
"tris"-buffered saline (TBS; 0.05 mol/1 tris, 0.1mol/l NaCl, pH 7.4) and
centrifuged at 20,000 x g for 15 min at 10 °C. The precipitate was washed 3
times with TBS and the liposomal pellet was dissolved in a 2% (w/v) solution
of n-octyl-6-D-glucopyranoside (Sigma) in TBS so that the final concentration
of cardiolipin was 3 mg/ml. This mixture was applied to a column of protein
A-'Sepharose CL 4B' (Pharmacia Fine, Upssala, Sweden). After extensive
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washing with 2% octylglucoside to remove the lipids, followed by washing
with TBS, the bound IgG was eluted with 1 mol/1 acetic acid and the eluates
were immediately neutralized by 3 mol/1 "tris". Fractions that contained IgG
were pooled and dialyzed against TBS before they were tested for aCL
antibodies content.
/or aCL
The assay for aCL antibodies essentially followed the procedure of Loizou et
al. (3). Briefly, microtiter plates were coated with cardiolipin (30 pi of a 50
Hg/ml solution of cardiolipin in ethanol per well). After evaporation of the
solvent, followed by washing with PBS, non-specific binding sites were
blocked with 10% bovine serum albumin (Sigma) in PBS for 1 h. Samples that
contained aCL antibodies were diluted in 10% bovine serum in PBS and
subsequently applied to the wells. The amount of aCL antibodies bound was
assessed by incubation with peroxidase-conjugated goat anti-human IgG. After
reaction of peroxidase with chromogenic substrate (tetramethylbenzidine) the
optical density at 450 nm (OD 450) was measured.
To determine binding affinity to liposomes, 25 |jJ of aCL antibodies were
mixed with 50 ^1 of cardiolipin:phosphatidylcholine:cholesterol (molar ratio
2.5:10:4) liposomes in the presence of 125 nl plasma, TBS or other test
materials. Final concentrations were 125 ^g/ml and 750 (ig/ml for aCL
antibodies and cardiolipin, respectively; aCL-cofactor was used at a final
concentration of 300 |ig/ml. After 30 min incubation at 37 °C mixtures were
centrifuged at 100,000 x g for 15 min and supernatants were evaluated for the
residual aCL activity using the standard ELISA described above. Data are
calculated according to the formula:
aCL bound = aCL total - aCL supernatants j . 100%
aCL total
In some experiments liposomes were used in which cardiolipin was replaced
by phosphatidylserine at a molar ratio for phosphatidylserine:
phosphatidylcholinexholesterol of 5:10:4 to correct for the difference in nett
charge between cardiolipin and phosphatidylserine or by phosphatidylcholine
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at a molar ratio for phosphatidylcholinexholesterol of 15:4.
o/ aCL-co/ac/or
aCL-cofactor was purified from plasma by ammonium sulphate precipitation
(50-90% saturation) followed by ion-exchange chromatography on QAE-
Sephadex in 50 mmol/1 "tris" buffer at pH 7.4. The column was eluted by a
salt-gradient and aCL-cofactor activity was recovered at 100 mmol/1 NaCl.
The proteins contaminating the eluted material were denatured by heat
treatment (90 °C for 10 min) and removed by centrifugation. The supernatant
fully retained aCL-cofactor activity and contained only one band as
demonstrated by Sodium-dodecylsulphate Polyacrylamide Gel Electrophoresis
(SDS-PAGE)
SDS-PAGE was done on a 7.5% polyacrylamide gel with a 4%
polyacrylamide stacking gel; after electrophoresis the gel was stained with
Coomassie Brilliant Blue.
Protein content of samples was assayed according to Sedmak and Grossberg
(9).
RESULTS AND DISCUSSION
Affinity-purified aCL antibodies from the plasma of both patients
reacted strongly with cardiolipin in a lipid-based ELISA.
Binding was little changed by substitution of cardiolipin by
phosphatidylserine, whereas binding of affinity-purified aCL antibodies was
abolished with phosphatidylcholine-coated wells (data not shown). In direct
binding experiments, in which aCL antibodies were incubated with liposomes
composed of a mixture of cardiolipin, phosphatidylcholine and cholesterol in
TBS, the 100,000 x g supernatant of this incubation still contained 100% aCL
activity - which indicated no aCL binding to liposomes. Replacement of TBS
by normal plasma reduced aCL activity in the supernatant to less than 5%
(Table) and a similar result was obtained when phosphatidylserine was
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Table L Binding of aCL antibodies to liposomes in the presence of plasma or
purified aCL-Cofactor
Composition of Control Plasma aCL-Cofactor
liposomes (molar ratios) (TBS)
CL:PC:Chol (2.5:10:4) 4% 96% 94%
PS:PC:Chol (5:10:4) 2% 89% 93%
PC:Chol(15:4) 0% 0% 2%
CL: cardiolipin; PC: phosphatydylcholine; Choi: cholesterol; PS: phosphatidylserine
substituted for cardiolipin. No aCL binding was found to liposomes composed
of phosphatidylcholine and cholesterol. These findings indicate that a plasma
component is involved in the binding of aCL antibodies to liposomes that
contain negatively charged phospholipids, as suggested by McNeil et al (12),
who also observed that binding of purified antiphospholipid antibodies to
immobilised phospholipid required the presence of plasma.
In the standard ELISA for aCL antibodies, different dilutions of the
antibody-containing samples are routinely made in 10% bovine serum in TBS;
the same medium is also used during the binding-step of aCL antibodies to the
cardiolipin- coated wells of the microtiter plates. We found that bovine serum
could be replaced by bovine plasma, human serum or human plasma but not
by purified bovine serum albumin. To further investigate the role of plasma in
aCL binding to cardiolipin, the standard ELISA was modified. Instead of
dilution in 10% bovine serum, constant amounts of aCL antibodies were
mixed with dilutions of normal pooled plasma and applied to the well.
Microtiter plates were further processed as described for the standard ELISA.
Fig. 1 shows the OD 450 as a function of the plasma concentration: a linear
correlation between OD and plasma concentration is observed from 0 to
0.5%, where a plateau is reached; similar findings were obtained with human
serum and bovine plasma or serum. Thus a plasma component is necessary for
aCL antibodies binding to immobilized cardiolipin. This plasma component,
termed aCL-cofactor, can be detected and measured by this modified ELISA
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The final step in the purification of aCL-cofactor involves heat treatment (10
min at 90 °C) followed by centrifugation to remove denatured protein
material. No loss of aCL-cofactor activity occurred in this step, but when the
preparation obtained was incubated with trypsin, aCL-cofactor became
inactive. SDS-PAGE showed aCL-cofactor to be a single chain polypeptide
with an apparent molecular weight of 50 kD (non-reduced) which increased to
70 kD upon reduction.
The specific activity of the cofactor preparation was 350 times that of
crude plasma; if 100% purity of this preparation was assumed, the plasma
concentration of aCL-cofactor would be approximately 0.2 mg/ml.
Purified aCL-cofactor was used to study the interaction of affinity-purified
aCL antibodies with liposomes (see Table). aCL-cofactor can be substituted
for plasma without loss of binding of aCL antibodies to liposomes that
contained negatively-charged phospholipid. Both supernatant and pellet of the
binding experiments with purified aCL-cofactor and/or aCL antibodies were
analysed by SDS-PAGE as shown in Fig. 2 for samples obtained after
incubations with cardiolipin-containing liposomes; similar results are obtained
with liposomes that contained phosphatidylserine. No binding of either of the
proteins was observed with liposomes without negatively-charged lipids.
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Without cofactor, no IgG was detectable in the 100,000 x g pellet of the
incubations (lanes 1, 2); with cofactor, approximately 60-70% of the IgG co-
sediments with the liposomes (lanes 3, 4). Incomplete binding of IgG was not
due to a limiting amount of aCL-cofactor and the unbound fraction of IgG in
the 100,000 x g supernatant no longer contained any aCL activity, so the IgG
fraction isolated from the plasma presumably contains antibodies other than
aCL antibodies with non-specific binding to the liposomes used in the affinity
purification procedure, or antibodies directed against other lipid-binding
proteins in plasma.
Fig. 2 shows that aCL-cofactor also binds to liposomes that contain
cardiolipin in the absence of IgG (lanes 5, 6). Binding of aCL-cofactor is not
dependent on or inhibited by the presence of calcium ions, so it is unlikely that
binding is mediated by gamma-carboxyglutamic acid residues on the cofactor.
We investigated the direct interaction between aCL-cofactor and affinity-
purified aCL antibodies in an ELISA in which the microtiter plates were
48
coated with different amounts of cofactor. After coating, a fixed amount of
aCL antibodies or normal IgG was applied to the wells in the absence of
phospholipid. aCL binding was proportional to the amount of aCL-cofactor in
the wells (Fig. 3) and no binding was found with normal human IgG. Thus
aCL antibodies of at least these two patients are not directed against
cardiolipin but against a protein with a high affinity for negatively-charged
phospholipid surface.
It is remarkable that the cofactor is not co-purified during the affinity
purification of aCL antibodies via cardiolipin-containing liposomes. Two
possible explanations might account for this: aCL antibodies only recognize
aCL-cofactor when bound to lipid or adsorbed on a microtiter plate; or aCL-
cofactor undergoes structural modification upon addition of octylglucoside
during aCL antibodies purification. Although aCL-cofactor is present in
normal human (and bovine) plasma in concentrations up to 0.2 mg/ml, its
identity is still obscure. The heat stability and behaviour on SDS-PAGE
(increase in apparent molecular weight upon reduction) suggest the presence
of several disulphide bridges. Preliminary experiments with purified
coagulation factors indicate that binding of aCL-cofactor to negatively-
charged phospholipid surfaces interferes with binding of the prothrombin
activating complex factor Xa-factor Va, leading to a diminished rate of
Q
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thrombin formation. Thus aCL antibodies may be directed against a naturally
circulating anticoagulant with high affinity towards negatively-charged
phospholipid surfaces.
The high purity of the aCL-cofactor allows analysis of aminoacid
composition, which is under investigation. However, the properties so far
identified (molecular weight 50 kD [non-reduced], 70 kD [reduced with 5% 6-
mercaptoethanol]; estimated plasma concentration 200 |ig/ml; heat stability;
calcium-independent binding to anionic phospholipids; support of aCL binding
to anionic phospholipids and inhibition of phospholipid-dependent coagulation
reactions) are very similar to those of f^-Glycoprotein I (apolipoprotein H),
the anticoagulant properties of which we have previously described (13).
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APPENDIX TO CHAPTER III
After the publication of Chapter HI, Dr Harris and collegues disputed
the necessity of a protein "cofactor" for the binding of aCL antibodies to
cardiolipin and other negatively-charged phospholipids (Harris EN, Pierangeli
S, Barquinero J, Ordi-Ros J. Anticardiolipin antibodies and binding of anionic
phospholipids and serum proteins. Lancet 1990; 336: 505-06).
The authors performed binding experiments of serial dilutions of an
aCL-positive serum to ELISA plate coated with cardiolipin (1.5 ng/well) or
100% adult bovine (or human) serum (100 ng/well). Bovine serum was used
as a source of aCL-cofactor. They observed net binding of aCL antibodies
only to wells coated with cardiolipin and not with serum. From these findings
they concluded that our report of the necessity of a plasma cofactor for aCL
binding to cardiolipin was invalid, otherwise aCL-positive serum would have
bound equally well to cardiolipin- and to serum-coated ELISA wells. Harris
and coworkers temptatively explained our findings because of phospholipid
contamination of the cofactor preparation. Moreover, our choice of liposomes
composed of a mixture of cardiolipin/phosphatidylcholine/cholesterol, instead
of cardiolipin alone, might have reduced the binding affinity of aCL
antibodies to cardiolipin, in this way explaining the lack of binding of affinity-
purified aCL antibodies to liposomes containing cardiolipin.
Finally, Harris and collegues evaluated the binding of total IgG
containing aCL antibodies to cardiolipin-coated ELISA wells. They observed
that the net binding of the patient IgG was much higher than that of normal
IgG when the IgG's were diluted in 10% solution of bovine serum instead of
buffer alone. According to the authors, this finding, which is clearly in line
with our results, was solely due to the better blocking capacity of non specific
binding by the 10% bovine serum solution compared to buffer.
Taken these data together, the authors concluded that aCL antibodies
bind to cardiolipin and not to a plasma protein.
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Here follows our reply (Bevers EM, Galli M. Lancet 1990; 336: 952-
53) to Dr. Harris and collegues' letter. In the present letter we report about
the identification of aCL-cofactor as the plasma protein B2-glycoprotein I:
B2-GLYCOPROTEIN I FOR BINDING OF ANTICARDIOLIPIN
ANTIBODIES TO CARDIOLIPIN
Sir,
In our (June 30, p. 1544) report we demonstrated that in comparison
with non-specific IgG there is no net binding of affinity-purified
anticardiolipin (aCL) antibodies to cardiolipin-coated ELISA plates or
cardiolipin-containing liposomes unless plasma or a protein purified from
plasma (aCL-cofactor) is present. We therefore conclude that aCL-cofactor
present in normal human (or bovine) plasma (serum) is essential for the
binding of aCL antibodies to cardiolipin or in general to negatively charged
phospholipid. This contention, which has been confirmed by McNeil et al. (1)
and Matsuura et al. (2) is refuted by Dr Harris and collegues (Aug 25, p 505)
by a "simple experiment". With the ELISA method, they show that aCL-
serum binds (almost) equally well to cardiolipin or cardiolipin/adult bovine
serum (ABS) coated wells, and does not bind much to wells coated with ABS
alone. From this observation they conclude that human or bovine sera are not
an absolute requirement for binding of aCL antibodies to cardiolipin.
However, we clearly demonstrated (Fig. 1 in our report) that dilutions of
plasma or serum down to 1% can be used before binding of aCL antibodies to
cardiolipin is substantially diminished. Since Harris and collegues use serial
dilutions of aCL-serum, they introduce sufficient cofactor (present in serum)
to support binding of aCL antibodies to cardiolipin.
Moreover, they do not clearly state whether the serial dilutions of aCL-serum
were made in phosphate-buffered saline (PBS) or - according to their own
recommendations (3, 4) - in 10% ABS/PBS. Furthermore, their argument that
coating of the ELISA plate with 100% ABS in the absence of cardiolipin
should also cause binding of aCL antibodies, if our statement were correct, is
54
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aCL+PBS
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non-specific IgG+10%
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Figure. Comparöon <ƒ binding o/;erio/ di'/urion ('m PASJ qf qöïniiy punyi«d aCL a/irifoxfi«
and non-speci/ic /gG to cardio/ipin-coatód ue/fr.
invalid since adsorption of cofactor will be seriously hampered because of
competion by large amounts of other proteins present in serum.
Harris and collegues review poorly other evidence disputing the role of
cofactor in binding of aCL antibodies to cardiolipin. They showed net
cardiolipin binding of purified IgG from a patient with antiphospholipid
syndrome (APS) compared with IgG from a healthy donor, whether these
preparations were diluted in 10% ABS/PBS or PBS alone. Our group obtained
similar results, but compared with binding in the presence of 10% ABS/PBS,
the binding of aCL antibodies in PBS alone becomes almost background,
despite the slightly increased binding over non-specific IgG in PBS (figure).
Finally, Harris and collegues show that preincubation of IgG-APS with
cardiolipin liposomes causes inhibition of binding to cardiolipin-coated ELISA
plates. No data are presented showing that this inhibition is not seen with
phosphatidylcholine liposomes, which is an essential control since prolonged
incubation might cause aspecific binding of IgG to lipid surfaces. Harris et al.
mention that net binding of IgG-APS was much higher than IgG donor when
10% ABS/PBS was used as diluent. The difference is explained by blocking
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(caused by 10% ABS) of non-specific binding of donor IgG, by which they
return to the original observation that led to the use of 10% ABS/PBS as
diluent in the aCL assay (6). However, we are convinced that the major effect
of 10% ABS observed is not suppression of non-specific binding but is
enhancement of the specific binding. In this respect it should be noted that
ABS cannot be substituted by 1% bovine (or human) serum albumin or
gelatin, which would be expected in suppression of non-specific binding.
We have demonstrated concentration-dependent binding of aCL
antibodies to cofactor-coated ELISA plates, even in the absence of cardiolipin,
and speculated that aCL antibodies are directed to cofactor rather than
cardiolipin. Although, despite the use of sensitive methods, we could not
detect any lipid-contamination in the cofactor or aCL preparation, we cannot
exclude the possibility that aCL antibodies are directed to a cofactor-
cardiolipin complex as proposed by McNeil et al. (1) rather than to cofactor
alone.
We have now established that the cofactor is I^-Glycoprotein I (B2-
GPI) on the basis of the sequencing of 20N-terminal aminoacids (kindly done
by Dr R.H.M. Ebberink, Applied Biosystems), in accord with McNeil and
collegues' data (2). The anticoagulant properties of this protein were
investigated in our laboratory in 1986 (5). The interaction of B2-GPI with
negatively-charged phospholipid vesicles was shown then to alter the
physicochemical structure of these vesicles. It is tempting to speculate that this
altered lipid bilayer structure results in exposure of the epitope to aCL
antibodies.
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CHAPTER IV
ANTICOAGULANT ACTIVITY OF B2-GLYCOPROTEIN I IS
POTENTIATED BY A DISTINCT SUBGROUP OF ANTI-
CARDIOLIPIN ANTIBODIES
Thromb HaemosUs 1992; 68: 297-300
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SUMMARY
Plasmas of 16 patients positive for both IgG anticardiolipin (aCL) and
lupus anticoagulant (LA) antibodies were subjected to adsorption with
liposomes containing cardiolipin. In 5 of these plasmas both the anticardiolipin
and the anticoagulant activities were co-sedimented with the liposomes in a
dose-dependent manner, whereas in the remaining cases only anticardiolipin
activity could be removed by the liposomes, leaving the anticoagulant activity
(LA) in the supernatant plasma. aCL antibodies purified from the first 5
plasmas was defined as aCL-type A, while the term aCL-type B was used for
antibodies in the other 11 plasmas, from which 2 were selected for this study.
Prolongation of the dRVVT was produced by affinity-purified aCL-type
A antibodies in plasma of human as well as animal (bovine, rat and goat)
origin. aCL-type B antibodies were found to be devoid of anticoagulant
activity, while the corresponding supernatants containing LA IgG produced
prolongation of the dRVVT only in /IM/TUJH plasma.
These anticoagulant activities of aCL-type A and of LA IgG's were
subsequently evaluated in human plasma depleted of l^-glycoprotein I (1$2-
GPI), a protein which was previously shown to be essential in the binding of
aCL antibodies to anionic phospholipids. Prolongation of the dRVVT by aCL-
type A antibodies was abolished using B2-GPI deficient plasma, but could be
restored upon addition of B2-GPI. In contrast, LA IgG caused prolongation of
the dRVVT irrespective of the presence or absence of B2-GPI.
Since B2-GPI binds to negatively-charged phospholipids and impedes
the conversion of prothrombin by the factor Xa/Va enzyme complex (Nimpf
et al. Biochim Biophys Acta 1986; 884: 142-49), comparison was made of the
effect of aCL-type A and aCL-type B antibodies on the rate of thrombin
formation in the presence and absence of B2-GPI. This was measured in a
system containing highly purified coagulation factors Xa, Va and prothrombin
and lipid vesicles composed of 20 mole% phosphatidylserine and 80 mole%
phosphatidylcholine. No inhibition on the rate of thrombin formation was
observed with both types of aCL antibodies when either B2-GPI or the lipid
vesicles were omitted. Addition of B2-GPI to the prothrombinase assay in the
presence of the lipid vesicles caused a time-dependent inhibition which was not
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affected by the presence of aCL-type B or non-specific IgG. In contrast, the
presence of aCL-type A antibodies dramatically increased the anticoagulant
effect of B2-GPI. These data indicate that the anticoagulant activity of aCL-
type A antibodies in plasma is mediated by 82-GPI.
INTRODUCTION
The so-called "antiphospholipid antibodies" represent a wide group of
autoantibodies, which include anticardiolipin (aCL) and lupus anticoagulant
(LA) antibodies. aCL antibodies are recognized by their ability to react with
anionic phospholipids in solid-phase immunoassays (1), whereas LA antibodies
prolong the clotting time of phospholipid-dependent coagulation reactions (2).
aCL and LA antibodies have long been considered to be closely related or
even identical autoantibodies. In fact, they occur concurrently in about 75% of
the cases. Moreover, LA antibodies were assumed to inhibit coagulation
reactions by competing with coagulation factors for the binding to anionic
phospholipid surfaces (3).
In recent years, however, it has been demonstrated that aCL IgG can be
separated from LA IgG in more than half of the patients with antiphospholipid
antibodies: in these cases aCL antibodies do not express anticoagulant activity,
whereas LA antibodies do not bind to anionic phospholipids in the
immunoassays (4-6). From these studies it became clear that aCL and LA
antibodies recognize different epitopes. Moreover, it was also demonstrated
that these antibodies require different protein "cofactors" to interact with
negatively-charged phospholipids (5-9): aCL antibodies require B2-
glycoprotein I (62-GPI) for their binding to anionic lipids (7-9), whereas LA
antibodies have been shown to recognize the complex of lipid-bound human
prothrombin (6).
However, it has been reported that some aCL antibodies can prolong
phospholipid-dependent coagulation reactions (3, 10). In agreement with this
finding, we have also observed that in some aCL and LA positive plasmas the
removal of aCL antibodies through adsorption to liposomes was accompanied
by a concomitant disappearance of LA activity (6). The aim of the present
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study was to investigate the mechanism by which these aCL antibodies prolong
the coagulation time of phospholipid-dependent coagulation reactions. In
particular, it was investigated whether 62-GPI plays a role in the expression
of the anticoagulant properties of aCL antibodies. For these reasons, we
studied the anticoagulant activity of aCL IgG in the presence and absence of
62-GPI both in plasma and in a system using highly purified coagulation
factors.
MATERIAL AND METHODS
This study initially included 16 patients with antiphospholipid antibodies, all
of them both aCL and LA positive as determined by solid phase immunoassay
(1) and activated partial thromboplastin time (aPTT) and/or kaolin clotting
time (2), respectively. In the plasma of 11 patients, aCL antibodies were
distinct from LA antibodies, i.e. could be separated by adsorption to
liposomes containing anionic phospholipids (Fig. 1, left panel). For the
purpose of the present study, 2 patients (patients 6 and 7) were selected from
this group of 11 patients. Clinical data of these patients were previously
reported (6). The other 5 patients, in which LA antibodies could not be
distinguished from aCL antibodies using the above procedure, were 3 males
and 2 females, aged 27 to 69 years. Two of them had a clinical history of
recurrent deep venous thrombosis, one patient had suffered from a
myocardial infarction and 1 other patient suffered from peripheral arterial
thrombosis. A mild thrombocytopenia was present in 1 patient (40xl(P
platelets/1). None of them fulfilled the criteria for diagnosis of Systemic Lupus
Erythematosus (11). AU patient plasmas contained polyclonal IgG.
n o/aCL/rom L4
To investigate whether aCL antibodies could be separated from LA antibodies,
the procedure described by Bevers et al. (6) was used. Briefly: liposomes
composed of a mixture of cardiolipin, phosphatidylcholine and cholesterol (at
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a molar ratio of 2.5:10:4, respectively) (all from Sigma, St. Louis, MO, USA)
were mixed with the plasma of the patients (3 mg of cardiolipin/ml of
plasma). After incubation for 30 min at 37 °C, the liposomes were removed
by centrifugation for 10 min at 12,000 x g. The liposome-free supematants
were analyzed for aCL and LA activity. aCL activity was determined by solid
phase immunoassay according to Loizou et al (1). LA activity was measured
by aPTT (3), using a mixture of 1 vol supernatant and 2 vol normal pooled
plasma. The diluted Russell viper venom time (dRWT) was measured after
addition of purified IgG to normal human and animal plasmas as described by
Thiagarajan et al. (12).
o/aCL
aCL antibodies were affinity purified from patients' plasma as previously
described (8). All aCL antibody preparations were adjusted to the same titer
in the solid phase immunoassy (1) prior to evaluation in coagulation assays.
Total IgG, devoid of aCL activity, was isolated from the supernatant of the
plasmas of patient 6 and 7 after liposomal adsorption using protein-A
sepharose CL 4B affinity-chromatography (Pharmacia Fine, Uppsala,
Sweden). These preparations are referred to as LA IgG's. Protein A affinity
chromatography was also used to obtain total non-specific IgG from normal
plasma.
Human B2-GPI deficient plasma, prepared as described by Oosting et al. (13)
was a kind gift of drs. P. G. de Groot, J.D. Oosting and R.H.W.M. Derksen
(Utrecht, The Netherlands).
62-GPI was purified from human plasma according to Poltz (14).
acriv/fy
To evaluate the effect of 62-GPI alone or in combination with aCL antibodies
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on the prothrombinase activity, highly purified coagulation factors of bovine
origin were used. Coagulation factors Xa, Va and prothrombin were purified
from bovine plasma according to Rosing et al. (15). The lipid source in this
assay were unilamellar vesicles, prepared by sonication in "Tris" buffered
saline (TBS: 0.05 mol/1 tris, 0.1 mol/1 NaCl, pH 7.4) of a mixture composed
of 20 mole % phosphatidylserine and 80 mole % phosphatidylcholine at a total
phospholipid concentration of 1 mmol/l. Prothrombinase activity was
measured essentially according to Nimpf et al. (16) with minor modifications.
Briefly, the prothrombinase assay was performed in TBS containing 0.5
mg/ml human serum albumin (Sigma, St. Louis, MO, USA) as follows: 115 pJ
lipid vesicles (diluted to 0.43 nmol/1 in TBS containing 0.5 mg/ml albumin)
were mixed with 25 |il non-specific- or patients' immunoglobulins (final
concentration 6-100 u.g/ml) in the presence or absence of 50 ul 82-GPI (1.4
mg/ml). After variable incubation times 10 u.1 CaCl2 (75 mmol/l) and 25 pi of
a mixture of factors Xa and Va (10 and 20 nmol/1, respectively) were added.
After 1 min thrombin formation was started by addition of 25 (i.1 prothrombin
(10 nmol/1). After another min, 25 p.1 aliquots were transferred from the
assay mixture into a cuvette containing 1 ml TBS/EDTA (2 mmol/l EDTA),
pH 7.4, to stop the reaction. Thrombin-specific chromogenic substrate S2238
(Kabi, Stockholm, Sweden) was added at a final concentration of 250 |imol/l
and from the change in absorbance at 405 ran the amount of thrombin was
calculated using a calibration curve made with known amounts of active site
titrated thrombin (15).
RESULTS
The plasmas of 16 patients with antiphospholipid antibodies (all positive
for both aCL and LA IgG) were incubated with cardiolipin-containing
liposomes. After sedimentation of the lipids, the supernatant plasmas were
evaluated for the residual LA and aCL activities. It was found that in 11 cases
aCL antibodies could be separated from LA antibodies (a typical example is
shown in Fig. 1, left panel). Further analysis of the separated LA IgG's
revealed that these antibodies were directed against the human
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prothrombin/phospholipid complex (cf. ref. 6 and Chapter II of this thesis).
In the present study we focused on the other 5 cases, in which both LA
and aCL antibodies were sedimented together with the liposomes (an example
representative for this group is shown in Fig. 1, right panel). aCL antibodies
were affinity-purified from the plasmas of these 5 patients using the liposome
adsorption procedure described before (8) and the effect of these antibodies
on coagulation reactions was investigated. For comparative reasons, aCL
antibodies were affinity-purified in the same way from the plasma of 2
patients belonging to the group of 11 patients. From these 2 patients LA
antibody prepaparations devoid of aCL antibodies were obtained as described
in Materials and Methods.
The effect of these immunoglobulin preparations was evaluated by
dRVVT in the plasma of different mammalian species (Table I). aCL
antibodies purified from the 5 patients caused prolongation of the dRVVT in
human as well as bovine, rat and goat plasma, although the extent of
prolongation by these antibodies seemed to vary somewhat with the plasma
source used. In contrast, aCL antibodies purified from the other 2 patients did
Anticoagulant Activity
2 3 0 1 2
Cardiolipin liposomes (mg/ml)
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Z>e/r pane/ J/IOIVJ a repraenrarive era^ip/e o/ aCi. separaè/e ,/rom L4. /?ig/i/ pane/ s/wwi a
representative eaïvnp/e o/co-adjorprwn o/fcor/i aCL and anncoagu/an/ acriviry Cre/erred ro as
aCL-rype /I anxioodjes;.
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Table I. Effect of aCL and LA antibodies on the dRVVT of plasma of
different mammalian species.
Sample
Buffer
N-IgG
aCL IgG
Patl
Pat 2
Pat 3
Pat 4
Pat 5
Pat 6
Pat 7
LA IgG
Pat 6
Pat 7
Human
(sec)
35.9
36.4
73.1
58.4
60.7
50.8
43.5
36.8
36.6
91.1
52.3
Bovine
(sec)
43.5
42.6
82.9
56.7
54.6
49.9
50.0
44.7
42.5
45.4
44.1
Rat
(sec)
27.0
27.5
51.2
41.0
37.7
34.7
33.4
28.6
27.9
29.8
29.8
Goat
(sec)
36.0
34.3
62.9
41.9
36.3
38.4
39.5
34.9
35.2
34.0
33.6
not possess anticoagulant activity, while their LA IgG's showed inhibitory
effect only in human plasma, as previously reported (6). Thus, aCL antibodies
could be separated into 2 groups: aCL-type A, which inhibited lipid-dependent
clotting reactions and aCL-type B, which did not possess anticoagulant
properties. Moreover, aCL-type A antibodies differed from LA antibodies in
their mode of action, since they exerted their anticoagulant effect not only in
human but also in animal plasmas.
To investigate whether l^-GPI was required for the expression of the
anticoagulant activity of aCL-type A antibodies in plasma, the effect of these
antibodies on the dRVVT of &2-GPI deficient plasma was evaluated. Table II
shows that in the absence of B2-GPI, aCL-type A antibodies did not express
anticoagulant activity. The addition of 0.2 mg/ml &2-GPI to this plasma
restored the original degree of prolongation of the dRVVT. On the other
hand, LA IgG exerted their anticoagulant effect irrespective of whether 62-
GPI was present or not. These data indicate that the inhibitory action of aCL-
type A antibodies on clotting reactions was dependent on B2-GPI. Moreover,
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Table II. Effect of aCL and LA IgG on the dRVVT of normal and 62-GPI
deficient plasma.
Sample
N-IgG
aCL IgG
Pat 1
Pat 2
Pat 3
Pat 4
Pat 5
LA IgG
Pat 6
Pat 7
Control plasma
(sec)
64.0
128.5
98.5
104.4
87.5
84.3
209.7
96.6
62-GPI deficient plasma
+ buffer
(sec)
67.5
74.1
63.5
68.5
67.0
64.7
197.3
98.0
+ 62-GPI
(sec)
67.3
144.1
99.5
98.2
83.3
81.0
200.3
97.3
the prolongation of the dRVVT indicates that these antibodies act at the level
of prothrombin conversion by the prothrombinase complex, i.e. factors Xa
and Va assembled on a phospholipid surface. As shown in Fig. 2, no inhibitory
effect of either aCL-type A or aCL-type B antibodies on the prothrombinase
activity was observed in the absence of 82-GPI. 62-GPI alone or in
combination with aCL-type B antibodies (or non-specific IgG) showed a time-
dependent inhibition of the prothrombinase assay. This process was relatively
slow, reaching 50% inhibition in 2 hours. In contrast, aCL-type A antibodies
were able to greatly enhance B2-GPI inhibition of the prothrombinase assay:
the 5 different aCL-type A IgG preparations showed inhibition ranging from
38 to 87% within 10 min. For reasons of clarity, the effect of aCL-type A
antibodies on the time course of inhibition by B2-GPI is shown in Fig. 2 for
the patients' aCL which exibited the highest inhibitory effect (87% in 10 min).
The aCL antibodies from the patient with the lowest inhibitory effect (38% in
10 min) is still appreciably different from the inhibition by 62-GPI alone or
in the presence of aCL-type B antibodies (10-12% in 10 min).
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DISCUSSION
In the present study we have demonstrated the existence of 2 types of
aCL antibodies, which behave differently in coagulation reactions in plasma.
To avoid confusion, we use the term aCL-type A to refer to the aCL
antibodies which prolong phospholipid-dependent coagulation reactions,
whereas the term aCL-type B is used for antibodies devoid of anticoagulant
activity.
Inhibition of coagulation reactions in plasma by aCL-type A antibodies
was strictly dependent on 62-GPI, since it was abolished in plasma depleted of
this protein. Only one aCL-type A preparation, which showed by far the
strongest anticoagulant activity, was still able to produce a slight prolongation
of the dRVVT of I^-GPI depleted plasma (Table II). This was presumably due
to the effect of these potent aCL-type A antibodies on the residual amount of
Bo-GPI (approx. 1% of the original level) in the depleted plasma. In fact, at a
fixed concentration of these antibodies, the prolongation of the dRVVT was
dependent on the amount of B2-GPI added to the depleted plasma (data not
shown).
B2-GPI is a plasma protein which binds to several negatively-charged
molecules, such as heparin, anionic phospholipids, deoxycholate and DNA (14,
16-18). In 1986, Nimpf et al. (16) have shown that B2-GPI, by binding to
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anionic phospholipids, inhibits the conversion of prothrombin by factors Xa
and Va. This inhibitory effect occurs at a relatively slow rate and requires at
least 60 min for full expression (16) (see also Fig. 2). We have observed that
aCL-type A, but not type B antibodies are able to enhance in a dose-dependent
way the inhibitory action of 82-GPI on prothrombin conversion. This effect
was produced within a few minutes and could thus explain the anticoagulant
activity of aCL-type A antibodies in plasma. It is important to underline that
aCL-type A IgG could not inhibit the prothrombinase assay when either the
procoagulant lipids or B2-GPI were omitted. It should also be emphasized that
the anticoagulant activity of aCL-type A antibodies in the prothrombinase
assay was independent of the source (bovine or human) of the coagulation
factors.
In recent years several authors have demonstrated that most of the aCL
antibodies lack the ability to inhibit coagulation reactions and that in these
cases the anticoagulant and anticardiolipin activities reside in 2 different
subgroups of antibodies (4, 5). These findings were obtained using affinity-
purification of aCL antibodies over solid-phase columns of immobilized
cardiolipin or phosphatidylserine. It has also been suggested that the
previously reported anticoagulant activity of aCL antibodies, that were
affinity-purified through adsorption to liposomes (3, 10), might be due to co-
purification of a mixture of phospholipid-binding antibodies (19). The
apparent necessity of high aCL antibody concentrations for the expression of
the anticoagulant effect further supported this concept (19). Although this
possibility cannot be ruled out in general, we could exclude that the different
behaviour of aCL-type A and B antibodies in coagulation reactions was solely
due to a difference in aCL titer.
The data presented here extend our studies on the mode of action of
antiphospholipid antibodies. Recently, we have demonstrated that LA
antibodies, distinct from aCL antibodies, inhibit phospholipid-dependent
coagulation reactions because they react with the complex of lipid-bound
human prothrombin (6). Thus, 2 acquired inhibitors of blood coagulation -
aCL-type A and LA antibodies - exist among the antiphospholipid antibodies
that hamper phospholipid-dependent coagulation reactions in plasma.
Therefore, both of them interfere with the same coagulation tests in vitro.
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However, LA and aCL-type A antibodies can be easily distinguished, since LA
antibodies exert their action only in Au/mzn plasma, whereas aCL-type A
antibodies inhibit coagulation reactions irrespective of the plasma source
(Table I). Conversely, prolongation of the clotting time by aCL-type A
antibodies is strictly f$2-GPI dependent, while LA antibodies do not require
the presence of this plasma protein. aCL-type B antibodies can only be
detected by solid phase immunoassay. The reason why this antibody is unable
to potentiate the anticoagulant property of 62-GPI is presently unknown.
Recently, Oosting and coworkers have demonstrated that depletion of
82-GPI by affinity chromatography with polyclonal anti-human B2-GPI
antibody normalized the dRVVT of 5/6 LA positive plasmas (13). In view of
the present findings, anticoagulant activities in these plasmas should originate
from aCL-type A antibodies. The one plasma out of these 6 in which the
prolonged dRVVT was not corrected upon removal of B2-GPI is then likely to
contain antibodies directed to lipid-bound /tuman prothrombin (LA),
comparable to patients 6 and 7 in Table II.
In view of these findings it now appears that the term "Lupus
Anticoagulant" may be a misnomer, which has been used improperly to refer
to 2 different inhibitors of blood coagulation: aCL-type A antibodies, which
recognize a complex of lipid-bound B2-GPI and LA antibodies, which are
directed to the complex of lipid-bound human prothrombin (6). In the future
a new terminology will probably become necessary to avoid further confusion
in the field of "antiphospholipid" research.
In conclusion, our data indicate that the interaction between
antiphospholipid IgG and anionic phospholipids is mediated by plasma
proteins and that at least three different types of these antibodies exist (aCL-
type A, aCL-type B and LA). At present, little is known about the mode of
action of IgM or IgA isotypes. Moreover, in infectious diseases such as
syphilis, aCL antibodies have been described which apparently do not require
62-GPI for their binding to anionic phospholipids (9). Antiphospholipid
antibodies, therefore, represent a family of rather heterogeneous antibodies
and more work is necessary for a better understanding of their mode of action
and to elucidate their role - if any - in the pathogenesis of thrombotic
complications associated with the antiphospholipid syndrome.
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CHAPTER V
EFFECT OF ANTIPHOSPHOLIPID ANTIBODIES ON
PROCOAGULANT ACTITY OF ACTIVATED PLATELETS AND
PLATELET-DERIVED MICROVESICLES
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SUMMARY
We have recently described the "in vitro" mechanism of action of
anticardiolipin (aCL) and lupus anticoagulant (LA) antibodies in patients with
the antiphospholipid syndrome. LA antibodies inhibit coagulation reactions in
plasma because they appear to recognize the complex of lipid-bound (human)
prothrombin, whereas aCL antibodies require 82-glycoprotein I (62-GPI) for
binding to anionic phospholipids. aCL antibodies can be divided into two
subgroups, according to their behaviour in lipid-coagulation reactions: aCL-
type A enhances the anti-coagulant effect of B2-GPI, whereas aCL-type B does
not.
In the present study we investigated the effect of purified aCL-type A
and B and of LA antibodies on the procoagulant activity of both Ca-ionophore
activated platelets and platelet-derived microvesicles in the presence and
absence of 62-GPI and human prothrombin, using an assay system with highly
purified coagulation factors Xa, Va and prothrombin from human and bovine
origin. In the absence of 82-GPI neither type of aCL was able to inhibit the
prothrombinase activity of platelets or microvesicles. However, a strong and
dose-dipendent inhibition of the prothrombinase activity of both platelets and
platelet-derived microvesicles was observed within a few minutes, when aCL-
type A antibodies were added in combination with B2-GPI. This inhibitory
effect was dependent also on the concentration of 62-GPI. Conversely, no
inhibitory effect of aCL-type B antibodies on platelet- (or microvesicle)
prothrombinase activity in the presence of 82-GPI could be observed.
LA antibodies were able to inhibit in a dose-dependent way the
procoagulant activity of activated platelets and platelet-derived microvesicles.
With two LA preparations this inhibition was only apparent when human
prothrombin was used as substrate, while a third preparation exibited its
inhibitory effect both in the presence of human and bovine prothrombin.
These data indicate that in the presence of their respective cofactors 82-
GPI and prothrombin, aCL and LA antibodies interact with the membrane of
platelets and microvesicles in a very similar way as previously observed for
their interaction with anionic phospholipid surfaces.
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INTRODUCTION
Lupus anticoagulant (LA) and anticardiolipin (aCL) antibodies are
distinct antibodies, which belong to the group of the so-called antiphospholipid
antibodies. Recently, evidence has been obtained that both LA and aCL
antibodies require protein cofactors to react with negatively-charged
phospholipids in order to express their immunological reactivities (1-4). LA
antibodies inhibit phospholipid-dependent coagulation reactions "in vitro"
because they recognize the complex of lipid-bound (human) prothrombin (1),
whereas aCL antibodies react with 1$2-Glycoprotein I (62-GPI) adsorbed onto
a phospholipid surface (2-4). Furthermore, aCL antibodies have been divided
into two distinct subgroups, according to their anticoagulant behaviour: aCL-
type A antibodies, which prolong phospholipid-dependent coagulation
reactions by enhancing the anticoagulant effect of 62-GPI and aCL-type B
antibodies, that do not promote the anticoagulant activity of 82-GPI (5).
It is increasingly appreciated that membranes from activated platelets
are an important source of negatively-charged phospholipids (i.e.
phosphatidylserine) to provide a catalytic surface for interacting coagulation
factors. In resting platelets, phosphatidylserine (PS) is predominantly located
in the cytoplasmic leaflet of the plasma membrane. Following activation by
different agonists, this asymmetric distribution is lost, leading to exposure of
PS at the outer surface, accompanied by shedding of procoagulant
microvesicles (6-8). In this sequence of events both platelets and platelet-
derived microvesicles expose a catalytic surface for the activation of
coagulation factor X and prothrombin by the so-called "tenase" and
"prothrombinase" complexes, respectively (9).
The effect of antiphospholipid antibodies on platelet procoagulant
activity has been frequently investigated in the last decade. Dahlback et al.
demonstrated that a polyclonal IgM with LA activity was able to inhibit the
prothrombinase activity expressed by platelets in a system with purified
coagulation factors (10). This finding was lately confirmed and extended,
using a method which allowed to measure platelet prothrombinase activity
directly in the plasma of the patients with antiphospholipid antibodies (11).
However, other investigators failed to show any interference of
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antiphospholipid antibodies with platelet procoagulant activities, suggesting
that platelets might "by-pass" the anticoagulant effect of LA antibodies (12,
13). Thus, it is presently unclear if and to what extent antiphospholipid
antibodies are able to inhibit platelet procoagulant activity. Moreover, the
putative role which membrane-bound (human) prothrombin and B2-GPI may
play in this respect is still unknown.
The aim of the present study was to re-evaluate the effect of affinity-
purified antiphospholipid antibodies on the prothrombinase activity of both
activated platelets and platelet-derived microvesicles using highly purified
coagulation factors of human and bovine origin. The different behaviour of
LA, aCL-type A and B antibodies was analyzed in the light of their
requirement for the cofactors prothrombin and B2-GPI, respectively. It is
shown that the anticoagulant characteristics of these antibodies in the presence
of activated platelets or platelet-derived microvesicles are very similar to
those previously observed in the presence of anionic phospholipid vesicles.
PATIENTS, MATERIALS AND METHODS
The study included 7 patients with antiphospholipid antibodies. Clinical data
were as follows: l.Ra., male, age 33, myocardial infarction; 2.Lo., male, age
51, recurrent thrombosis of cerebral and renal arterioles; 3. Gh., age 39,
recurrent arterial thrombosis of the legs; 4.Ma., male, age 69, recurrent
peripheral venous thrombosis; 5.Se., male, age 52, superficial
thrombophlebitis; 6. Ra, female, age 32, recurrent peripheral venous
thrombosis; 7. Vi., female, age 54, retroperitoneal hematoma. None of these
patients met the revised criteria of the American Rheumatism Association for
the diagnosis of Systemic Lupus Erythematosus (14).
All patients were IgG aCL antibodies positive as determined by ELISA,
according to the method described by Loizou et al. (15). A phospholipid-
dependent inhibitor of coagulation was present in all cases. In fact, the
activated partial thromboplastin time (aPTT), kaolin clotting time (KCT) (16)
and dilute Russell viper venom time (dRVVT) (17) performed with the plasma
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of the patients were prolonged and not corrected in the 1:1 mixture with
normal pooled plasma, according to the criteria proposed by the SSC
subcommittee for the standardization of LA (18).
Anfifcorfy preparatio
aCL antibodies were purified from patient plasmas by adsorption to
cardiolipin containing liposomes and subsequent affinity-chromatography over
protein-A sepharose CL-4B (Pharmacia Fin, Upssala, Sweden) as described
earlier (2). All aCL preparations were verified to require 62-GPI for binding
to cardiolipin-coated plates in solid phase immunoassay. For reasons of
comparison in coagulation assays, aCL preparations were adjusted to the same
titer using the standard immunoassay according to Loizou et al. (15).
aCL antibodies were divided into two groups:
aCL-type A antibodies, isolated from the plasma of patients 1-4, were
found to prolong the dRVVT of both human- and animal (bovine, rat and
goat) plasma. The anticoagulant effect of these aCL antibodies was previously
shown to be critically dependent on the presence of B2-GPI (5).
aCL-type B antibodies were purified from the plasma of patients 5-7
and were demonstrated to have no anticoagulant properties.
LA antibodies were found to be present in the total IgG fraction of the
plasmas from patients 5-7, obtained by protein A sepharose affinity
chromatography. LA antibodies present in total IgG from patients 5 and 6
were previously characterized to recognize lipid-bound human prothrombin
(1), while LA antibodies from patient 7 were not studied before. The
inhibitory effect of these antibodies, in contrast to aCL-type A, appeared to be
independent of B2-GPI.
Coagulation factors Xa and Va were purified from bovine plasma according
to Rosing et al., (19). Prothrombin was purified from both bovine (19) and
human (20) plasma. Final concentrations of the various components in the
prothrombinase assay were: 1 nmol/1 factor Xa, 2 nmol/1 factor Va, 1 |imol/l
prothrombin and 3 mmol/1 CaC^. Calcium ionophore-activated platelets were
used in the assay at a concentration of 2,000/^1 and isolated platelet-derived
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microvesciscles were used at dilutions giving prothrombinase activities similar
to that of 2,000/p.l ionophore-activated platelets. In some experiments,
phospholipid vesicles (0.2 ujnol/1) were used instead of platelets.
To assess the inhibitory effect of aCL, these antibodies were preincubated with
platelets or microvesicles in presence of absence of 62-GPI for various time
intervals before addition of coagulation factors. In this setup, prothrombinase
was initiated by addition of prothrombin.
For determination of the anticoagulant effect of LA antibodies, the assay was
slightly modified: total IgG was preincubated for 10 min with human- or
bovine prothrombin and activated platelets or microvesicles in the presence of
3 mmol/1 CaCl2- In this particular case, prothrombinase was initiated upon
addition of a mixture of factors Xa and Va.
In both assay systems the amount of thrombin formed at a fixed time interval
after initiation of the reaction was measured by transferring 25 fo.1 reaction
mixture into a cuvette containing 1 ml EDTA (2 mmol/1) in "tris" buffered
saline (0.05 mol/1 tris, 0.1 mol/1 NaCl), pH 7.4 to stop the reaction.
Thrombin-specific chromogenic substrate S2238 (Kabi, Stockholm, Sweden)
was added at a final concentration of 250 (imol/1 and from the change in
absorbance at 405 nm the amount of thrombin was calculated using a
calibration curve made with known amounts of active site titrated thrombin
(19). Inter-assay coefficient of variation of the prothrombinase measurement
was less than 5%.
82-GPI was purified from human plasma according to Poltz (21).
Washed human platelets were prepared from blood drawn from healthy
volunteers as described elsewhere (22). Platelets were finally resuspended in
Hepes buffer (136 mmol/1 NaCl, 2.7 mmol/1 KC1, 2 mmol/1 MgC^, 10 mmol/1
Hepes, 5 mmol/1 glucose, 0.5 mg/ml human serum albumin, pH 7.5) and
activated by incubation for 5 min at 37 °C with 1 [i.mol/1 Ca-ionophore
A23187 (Calbiochem) in the presence of 3 mmol/1 CaC^. Platelet-derived
microvesicles were separated from Ca-ionophore activated platelets by
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differential centrifugation as described by Comfurius et al. (8).
I/m'/ame/far vesic/es
Unilamellar vesicles were prepared by sonication of mixtures of brain-
phosphatidylserine (PS) and egg-phosphatidylcholine (PC) at different molar
ratio in "tris"-buffered saline according to Rosing et al. (19).
RESULTS
The time-dependent effect of aCL-type A and B antibodies, obtained
from two representative patients (numbers 1 and 5, respectively), on the
prothrombinase activity of both activated platelets and platelet-derived
microvesicles is shown in Fig. 1. Irrespective of the procoagulant membrane
surface, no inhibitory effect of either type of aCL antibodies was observed in
the absence of 82-GPI. Also, B2~GPI either alone or in combination with
normal IgG or aCL-type B was not able to inhibit the prothrombinase activity
B2-GP1 alone or
+ N-IgG or aCL-lypc B
0
aCL-type A + B2-GPI
15 30 45 60 0 15 30 45 60
Incubation time (min)
Fig 1. rimc-dependen/ effect o/ aCZ-fype /4 am/ B a«///>oaïej on »/ie pror«romZ>/'nare activity
<?ƒ acrivared p toe/ets ("/e/r pane/j and p&ue/er-den'ved microvesic/es (right pane/J'" ' ^ presence
and a&sence o / ^ - C P / ("250 /ig/m/| aCL-rypc A Cparienx /) war i«ed at a/ina/ concentration
o /9 / ^g/m/, wnereas aCL-fype S (patien/ 5) was used at 40 //g//n/. W/tn non-ipeci/ïc /gC tne
reiuiu were idenrica/ to tnose obtained wirn aCL-fype iB fnot 5nown). /*rotnromZ?inaje acrivtty
« expressed aj percentage o/ tne activity in the absence o//gC or^-G/*/, 700% corresponds
to a rate o/ /S6 nA/ tnromAin/ormedper minute.
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of activated platelets to any appreciable extent within the time course of the
experiments, although a minor inhibition was apparent in the presence of
platelet-derived microvesicles. On the other hand, a rapid time-dependent
inhibition of the prothrombinase activity of both activated platelets and
platelet-derived microvesicles was produced by aCL-type A antibodies
together with B2-GPI (Fig. 1, left and right panel, respectively). This
inhibition was dependent on the concentration of both aCL-type A antibodies
(Fig. 2) and B2-GPI (data not shown). Very similar results were obtained with
the aCL-type A antibodies from patients 2, 3 and 4, and the aCL-type B
antibodies from patients 6 and 7. The effects of each aCL-type A and B
antibody preparation in combination with 62-GPI on the prothrombinase
activity of both activated platelets and platelet-derived microvesicles, after 10
min pre-incubation with the respective platelet membranes, are summarized in
Table I.
Fig. 3 shows the concentration-dependent effect of total IgG containing
LA antibodies from patient number 5 on the prothrombinase activity towards
human prothrombin in the presence of activated platelets or platelet-derived
microvesicles. As also shown in Table I, the inhibition observed by the IgG
preparation obtained from patient number 5 is representative for the three
patients studied. No inhibition of prothrombinase activity was observed in the
absence of the procoagulant platelet surface or that of the platelet-derived
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Table I. Inhibition of the prothrombinase activity of activated platelets and
platelet-derived microvesicles by aCL- and LA antibodies
Patient IgG mg/ml Residual Prothrombinase Activity (%)
activated platelets platelet microvesicles
N-IgG 0.10 100 100
aCL-type A
1 0.09 63 50
2 0.08 55 46
3 0.05 66 56
4 0.06 70 60
aCL-type B
5 0.04 98 97
6 0.03 100 97
7 0.12 99 99
LA-IgG
5 6.90 59 48
6 6.90 70 61
7 1.80 57 49
profnromWnase activities are measured a/rer /0 min preincuiation wi//i activated
ptoe/ets or microvesic/es in rfce presence »ƒ eitner 2S0/ig/m/j32-G/V (/or aCL antibodies) or /
/imo/// Ziuman protnromWn (/or L4 antibodies). For measuring L.4 activity o/ pafienfs 5-7
fofa//gG were used, since t/ie presence o/aCL-type B does nol inter/ère in t/ie pror/iromAinase
assay. Data represent average o/ i independent experiments; S.D. was /ess fnan 5%.
microvesicles (data not shown). The inhibition was dependent on the
concentration of LA antibodies and reached a maximal effect within 7 to 10
min. LA antibodies purified from plasma of patients number 5 and 6 only
showed inhibition of the prothrombinase towards membrane-bound human
prothrombin, whereas the IgG preparation obtained from patient number 7
exibited its inhibitory effect irrespective of whether human or bovine
prothrombin was the substrate for prothrombinase. Also, in a prothrombinase
system containing sonicated PS/PC instead of platelets, the LA antibodies from
patient number 7 produced appreciable inhibition in the presence of both
human and bovine prothrombin (data not shown), unlike the LA antibodies
from patients 5 and 6, which were only inhibitory when human prothrombin
was used as substrate.
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Table II. Inhibition by LA and aCL-type A antibodies on prothrombinase
activity of lipid vesicles as a function of the molar ratio PS/PC.
PS/PC mol %
5/95
10/90
20/80
Residual Prothrombinase Activity (%)
aCL-type A LA
55
42
15
80
69
40
/nWW/ory ejjfecr o/ aCZ. >vas measured using aCL-fype i4 a^fiiodiej /rom panenr 7 af a /ina/
concen/rafion o/ 97 p^/m/ «n f/ie presence o /J^-C^ f280 /^g/m7,); rora/ 7gG /rom par/en/ 5
were used af a concenfrarion p/6.9 mg/m/ (/ïna/ concenfrafion) fo mearure f/ie inWWrion fry
M. Daw represent average o/J independenf experimen/s; Si?, was /ess tnan 6%
Since platelet-derived microvesicles may expose higher surface
concentration of PS than the activated platelets themselves (8), we also studied
the inhibitory effect of LA and aCL-type A antibodies on the prothrombinase
activity of phospholipid vesicles with variable mole fractions of PS. Table II
shows that the inhibition expressed by both antibodies is progressively
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enhanced on increasing the mole fraction of PS of the lipid surface. This may
explain why the inhibitory effect of both antibodies on prothrombinase
activity is higher in the presence of platelet-derived microvesicles as
compared to activated platelets (cf. Table I).
DISCUSSION
i
In this study we have demonstrated that LA and aCL-type A, but not
aCL-type B, antibodies inhibit the prothrombinase activity expressed by
activated platelets and platelet-derived microvesicles.
The inhibitory effect of aCL-type A antibodies on platelet
prothrombinase activity was strictly dependent on the presence of the plasma
cofactor 62-GPI as was previously found for prothrombinase activity in the
presence of anionic phospholipid vesicles (5). Since aCL-type A antibodies
recognize 82-GPI bound to anionic phospholipids (2-4), our data strongly
suggest that they equally well recognize 62-GPI bound to activated platelets or
platelet-derived microvesicles.
Conversely, aCL-type B antibodies, although equally able to recognize lipid-
bound 62-GPI, do neither inhibit prothrombinase in the presence of lipids (5)
nor in the presence of platelets and platelet-derived microvesicles (this study).
The obvious difference in anticoagulant effect between the two types of aCL
antibodies may reflect recognition of different epitopes of membrane-bound
62-GPI, which are expressed irrespective of whether this cofactor is bound to
lipids, platelets or platelet-derived microvesicles.
LA antibodies have recently been shown to recognize prothrombin
bound to anionic phospholipid vesicles, leading to inhibition of
prothrombinase activity in the presence of lipids (1). The present data show
that LA antibodies are also capable to inhibit prothrombinase activity of
platelet- and platelet-derived microvesicle membranes. These findings suggest
that the mechanism of inhibition of prothrombinase by LA antibodies in the
presence of platelets resembles that in the presence of lipids. Also, we recently
observed that LA antibodies bind to procoagulant red cell ghost membranes
only in the presence of prothrombin and calcium, while aCL antibodies
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require Bo-GPI to interact with these membranes (see Chapter II of this
thesis). In a previous article, we reported that LA antibodies were able to
inhibit the phospholipid-dependent coagulation reaction only in human plasma,
since they were directed towards the complex of lipid-bound /lu/nan
prothrombin (1). We have now been able to identify an IgG preparation
containing LA antibodies (patient number 7), which prolongs coagulation
times in lipid-dependent coagulation assays in plasma from different
mammalian species (human, bovine, rat and sheep; data not shown) and which
inhibits prothrombinase activity in the presence of procoagulant membranes
irrespective of whether human or bovine prothrombin is used as a substrate.
Although this may indicate that LA antibodies from patient number 7 could
recognize lipid-bound prothrombin in a less species-specific way than LA
from patients 5 and 6, it cannot be excluded that the antibodies from patient 7
are directed to lipid-bound factor Xa and/or Va.
We consistently observed that the rate and extent of inhibition of LA
and aCL-type A antibodies on the prothrombinase activity was higher in the
presence of platelet-derived microvesicles than in the presence of activated
platelets. While we cannot exclude the possibility that this may reflect
interaction of the antibodies with differential expression of the Fc receptors
on the membranes of platelets and platelet-derived microvesicles, it seem
more likely that this difference is due to the fact that microvesicles expose
higher surface concentrations of PS than activated platelets (8). The
experiments with vesicles containing increasing concentrations of PS clearly
show that the inhibitory effect of LA and aCL-type A antibodies was a
function of the molar PS/PC ratio. Moreover, it is known that the extent of
binding of B2-GPI and prothrombin is directly proportional to the PS density
on the procoagulant surface (23, 24).
In the present experiments we could hardly detect any inhibition of
platelet prothrombinase after 2h incubation with 62-GPI alone. Only after
overnight incubations of 62-GPI with activated platelets and platelet-derived
microvesicles, appreciable inhibition (some 70%) of prothrombinase could be
observed. This behaviour is not in agreement with that previously reported by
Nimpf et al. (23), who observed 75% inhibition of Ca-ionophore activated
platelet-dependent prothrombinase activity by B2-GPI after 60 min. While this
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discrepancy remains unclear, it cannot be excluded that the B2-GPI
preparation used earlier (ref. 23) may have been contaminated with aCL
antibodies, the more so as this preparation was purified from pooled plasma.
At that time, the relationship between 82-GPI and aCL antibodies was
unknown.
In the last years, several authors have studied the effect of
antiphospholipid antibodies on the procoagulant activity of platelets both in
systems with purified coagulation factors (10) and in plasma (11). These
authors concluded that the inhibitory effect was due to a direct binding of the
antibodies to the platelet membrane. These findings are only seemingly in
contradiction to our data. In fact, Dahlback and coworkers (10) pre-incubated
prothrombin with the phospholipid surface before adding the antibodies, in
this way allowing the formation of the antigenic target of LA antibodies. In
the other case, the assays were performed directly in plasma, where both
prothrombin and B2-GPI are present (11). Other authors have investigated the
binding of antiphospholipid antibodies to platelets. aCL antibodies have been
shown to bind to the membrane of activated or freeze-thawed platelets only
when serum was used as the source of antibodies (25). More recently, this
binding has been demonstrated to be 62-GPI dependent (26). These data are
clearly in line with our findings. Also, our observations that LA antibodies
presumably recognize membrane-bound prothrombin may explain why most
authors failed to demonstrate direct binding of LA antibodies to the
membrane of activated platelets (13, 27, 28). However, Chesterman et al. (26)
have recently reported preliminary data about the binding properties of LA
antibodies, which are in contrast with our observations. These authors
described affinity-purified LA antibodies, which apparently could bind to
thrombin activated platelets in the absence of plasma components. It cannot be
a priori excluded though, that these LA antibodies require a protein cofactor
released by activated platelets in order to interact with the platelets membrane.
It should be emphasized that these intriguing findings illustrate heterogeneity
among antiphospholipid antibodies.
In conclusions, our data indicate that antiphospholipid antibodies bind to
the procoagulant membranes of activated platelets and platelet-derived
microvesicles via their plasma cofactors. This interaction might have
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physiological implications, expecially with respect to platelet-derived
microvesicles, which have been suggested to be present in the plasma of
patients with antiphospholipid antibodies (16).
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CHAPTER VI
GENERAL DISCUSSION
Lupus anticoagulant (LA) and anticardiolipin (aCL) antibodies belong
to the group of the so-called antiphospholipid antibodies (1). Their presence
defines a clinical condition named "antiphospholipid syndrome", which is
characterized by arterial and/or venous thrombosis, recurrent abortions and
thrombocytopenia (1). The relationship between antiphospholipid antibodies
and these haemostatic events has prompted a number of researchers to
investigate whether these antibodies may play a pathogenetic role in the
development of the thromboembolic complications. Since antiphospholipid
antibodies have long been considered to bind to negatively-charged
phospholipids, which are an essential constituent of cell membranes, they have
been thought to interfere with the functions of blood cells (such as platelets,
mononuclear and endothelial cells) (2), producing an imbalance between their
pro- and anticoagulant properties (3). However, in spite of a wealth of
research, no conclusive demonstration of such a mechanism has been obtained
so far. The reasons for these frustrating results are multiple and stem, at least
in part, from the heterogeneity of antiphospholipid antibodies and the
complexity of their immunological targets (see below). In fact, over the last
few years it has become evident that, although frequently concurrent, LA and
aCL antibodies may be separated into two groups of antibodies, which express
a different behaviour in coagulation and immunological reactions (4, 5).
In this thesis we have tried to elucidate the mechanism of the "in vitro" action
of aCL and LA antibodies in the antiphospholipid syndrome, showing that:
1. the interaction of aCL and LA antibodies with negatively-charged
phospholipids is mediated by at least 2 plasma proteins, identified as 69-
Glycoprotein I (B2-GPI) and prothrombin, respectively.
2. at least 3 different types of antiphospholipid antibodies can be
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recognized - aCL-type A, aCL-type B and LA antibodies - which are
distinguishable on the basis of their anticoagulant properties in plasma and
their immunological reactivity in the immunoassays.
LA and aCL-type A antibodies behave as acquired inhibitors of coagulation.
LA antibodies inhibit phospholipid-dependent coagulation tests because they
recognize prothrombin bound to a lipid surface, whereas aCL-type A
antibodies enhance the anticoagulant properties of 82-GPI. Conversely, aCL-
type B antibodies are devoid of anticoagulant effect.
Due to its pivotal role in the process of blood coagulation, prothrombin
is one of the most studied and best known plasma proteins. In contrast, less
information is available for 82-GPI, although it has been described for the
first time already in 1961 (6). Thus, we will focus here on the biochemical
and functional properties of 82-GPI.
82-GPI is a single chain polypeptide, with an apparent molecular weight
of 50 kD (unreduced), which increases to 70 kD upon reduction. Its amino
acid sequence was reported for the first time in 1984 (7). The protein appears
rich in prolin and cystein residues and consists largely of repeated units
approximately 60 amino acids in length. It contains 11 disulfide bridges (8):
this may explain the shift in molecular weight following treatment with a
strong reducing agent. More recently, other groups have reinvestigated the
aminoacid sequence of 62-GPI (8-10), which appears to be highly
conservated. In fact, the human and rat polypeptides show more than 80%
homology (9). 82-GPI has a plasma concentration of approximately 4 nmol/l
(0.2 mg/ml) and its site of biosynthesis is probably the liver. About 40% of
the protein is associated with different classes of lipoproteins (especially those
rich in triglycerides) (11), the remainder circulates free in plasma.
B2-GPI is able to bind not only to negatively-charged phospholipids, but
also to other anionic molecules, such as DNA, deoxycholate, kaolin and
heparin (12-15). It has also been reported that 82-GPI binding is able to
modify the structural arrangement of anionic phospholipid. This has been
observed for phosphatidylcholine/phosphatidylserine vesicles, which form
stacked discs (16) and for cardiolipin, which is changed from the lamellar into
the hexagonal (HJJ) phase (17). In this way it is possible to explain the cross-
reactivity that some antiphospholipid antibodies exhibit, which extends beyond
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anionic phospholipids to include DNA and phospholipids in hexagonal
phase (18, 19).
B2-GPI has been shown to have several anticoagulant properties "in
vitro", among which are the ability to inhibit contact activation of blood
coagulation (12), ADP-induced platelet aggregation (21) and platelet- and
phospholipid-dependent prothrombinase activity (see below) (16) and the
ability to bind and inactivate activated protein C (20). In spite of this "in
vitro" behaviour, the physiological role of 62-GPI is still unclear. In fact,
reduced plasma levels of this protein do not seem to confer an increased risk
of thrombosis (22). In patients with antiphospholipid antibodies we have
measured either normal or increased levels of 62-GPI (23). The clinical
relevance of this finding remains to be established, since no correlation was
observed between 62-GPI levels and aCL or LA activities in plasma or the
thromboembolic history of the patients. More recently, similar data have been
reported also by Vlachoyannopoulos and coworkers (24) and by Tincani and
coworkers (25).
In 1990 the requirement of B2-GPI for aCL antibodies to bind to
anionic phospholipids was independently reported by our group (chapter III)
and two other laboratories (26, 27). A main difference, however, existed
between our own and McNeil and coworkers' findings. In fact, we observed
that 62-GPI itself, adsorbed on an ELISA plate, behaves as a direct antigen for
aCL antibodies. More recently, these data have been confirmed by another
group (28). In contrast, McNeil and coworkers reported aCL binding to 62-
GPI only in the presence of negatively-charged phospholipids, thus suggesting
that the antibodies recognize an epitope expressed by the complex of lipid-
bound B2-GPI (26). Several possibilities may account for this discrepancy. In
fact, we cannot exclude that aCL antibodies purified from different patients
may recognize different epitopes on B2-GPI, which in seme cases may include
a phospholipid portion. Another possibility is the lipid contamination of our
82-GPI, which is dependent on the purification procedure. We have
investigated this possibility, comparing the antigenic activity of B2-GPI before
and after lipid extraction by ELISA. One would expect that, if aCL antibodies
recognize the complex of lipid-bound 62-GPI, the lipid extraction procedure
should reduce the antigenic activity of 62-GPI. On the contrary, we have
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observed an enhancement of aCL binding to B2-GPI coated ELISA wells
(unpublished observation). Moreover, we have obtained preliminary evidence
that aCL antibodies do not bind to 62-GPI in free solution (unpublished data).
Taken these observations together, we hypothesize that aCL antibodies
recognize a cryptic epitope that is made available upon binding of 82-GPI to a
surface, which is not necessarily represented by negatively-charged
phospholipids only, but may be polystyrene, PVC (or others) as well (Fig. 1).
Data in favour of this hypothesis have been recently put forward by Koike and
coworkers, who observed that B2-GPI is able to bind to the carbonilic residues
of gamma-irradiated polystyrene ELISA plates (29). Moreover, Verrier-Jones
demonstrated that B2-GPI undergoes a conformational change upon binding to
cardiolipin (25). This observation represents an alternative to the above
mentioned findings of Nimpf and coworkers (16) and Janoff and coworkers
(17). However, one cannot exclude the possibility that at least some aCL
antibodies are, actually, directed against B2-GPI, as suggested by the recent
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observation by Viard et al. (30), who detected anti &2-GPI antibodies in a very
high proportion of patients with the antiphospholipid antibodies.
Furthermore, monoclonal anti B2-GPI antibodies have been shown to express
anticoagulant effects similar to those of antiphospholipid antibodies (31).
Thus, it is evident that more work will be necessary in the future to
characterize the antigenic target of antiphospholipid antibodies.
Since their first presentation, the data concerning the requirement of
82-GPI for the interaction between aCL antibodies and their putative antigens
have raised a great deal of interest. The importance of this new finding is
underlined also by the fact that the role of B2-GPI as cofactor of aCL
antibodies has been strongly disputed and even rejected by some authorities
for a long time (32, 33). Anyway, most of the disagreement on this subject has
been overcome by now, the leading opinion being in favour of B2-GPI. This
has been clearly pointed out during an International Workshop devoted to &2-
GPI as aCL-cofactor (25) and also during the "V International Symposium on
Antiphospholipid Antibodies" held in S. Antonio on September 9-12, 1992.
Among the major topics discussed during the Symposium, in fact, many
presentations were dealing with the elucidation of the epitope(s) of aCL
antibodies and the immunological and anticoagulant characterization of poly-
and monoclonal anti- B2-GPI antibodies. This type of antibodies is particularly
interesting, since they can, actually, be considered part of the family of
antiphospholipid antibodies.
The interaction between aCL antibodies and B2-GPI in coagulation tests
results, as already mentioned, in recognition of two distinct subtypes: aCL-
type A, which are able to prolong the coagulation times of phospholipid-
dependent coagulation tests in a strictly B2-GPI-dependent fashion and aCL-
type B, which are devoid of anticoagulant activity (Chapter IV). The
anticoagulant mechanism of action of aCL-type A antibodies resides on the
enhancement of B2-GPI binding to the anionic phospholipid surface, which
does no longer occur in 30 to 60 min (16) but is accomplished within 3-5 min.
In this way, B2-GPI can express its anticoagulant effect also on the coagulation
tests currently performed for the detection of antiphospholipid antibodies.
Recently, a publication by Oosting and coworkers appeared, showing that the
removal of B2-GPI from plasma by an anti B2-GPI affinity column abolishes
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the anticoagulant activity of plasma containing antiphospholipid antibodies and
that the anticoagulant effect is restored by replenishment with B2-GPI (34).
These data closely resemble ours, although these authors neither elucidated the
precise mechanism of action of the antibodies nor identified these antibodies as
LA or aCL.
aCL-type A anticoagulant action in plasma can explain the inhibition of
the phospholipid-dependent coagulation tests only in a minority of
antiphospholipid antibody positive plasmas. In fact, as described in Chapter II,
in about 2/3 of the cases LA antibodies could be separated from aCL
antibodies. In these cases the effect of LA antibodies in plasma is due to the
recognition of the complex of phospholipid-bound human prothrombin. Our
findings extend the observation, made by Loeliger already in 1959 (35), on a
patient with SLE, whose LA antibodies were associated with
hypoprothrombinemia. The author suggested that prothrombin is the
"cofactor" necessary for the expression of LA activity in plasma and that a
reduced level of prothrombin results from the formation and subsequent
scavenging from circulation of the LA antibodies/prothrombin complex on the
phospholipid surface. In the following years low levels of prothrombin were
repeatedly reported in patients with LA antibodies (36, 37). Nevertheless, LA
"cofactor" has been variously identified (38, 39), and its existence even denied
(40).
Fleck and coworkers observed that most LA antibodies were able to cross-
react with prothrombin without affecting its enzymatic active site, in this way
inducing a variable degree of hypoprothrombinemia (41). Interestingly, these
authors failed to demonstrate a direct binding of LA antibodies to purified
prothrombin and they could not exclude that phospholipids might participate
to the immune complex formation. These data are in good agreement with our
findings, which clearly demonstrate the necessity of both a phospholipid
surface and prothrombin for the expression of the anticoagulant activity of
LA antibodies. Recently, we have performed direct binding experiments
which rule out the possibility that the LA effect was due to inhibition of
prothrombin binding to the anionic phospholipid (see Chapter II of this
thesis). Thus, the other obvious possibility remains to explain the
anticoagulant mechanism of LA antibodies, that is the recognition of the
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complex of lipid-bound prothrombin. In this respect, it is tempting to
speculate that LA antibodies might recognize an epitope that prothrombin
exposes only after binding to a phospholipid surface, thus simulating the
condition already proposed for aCL antibodies and 62-GPI (Fig. 1).
To approach a more physiological condition, the anticoagulant activity
of LA and aCL-type A antibodies was evaluated in presence of either activated
platelets or platelet-derived microvesicles, which replaced artificial
phospholipid vesicles as procoagulant surface (Chapter V). Also under these
conditions, prothrombin and B2-GPI appeared to be absolutely necessary for
the expression of LA and aCL anticoagulant effect, respectively. The extent of
inhibition was found to depend more on the amount of phosphatidylserine
exposed on the outer leaflet of the procoagulant membrane than on the type of
surface used, thus confirming a previous observation by Galli and coworkers
(42). These findings also give an explanation for the so-called "by-passing"
effect of activated or lysed platelets towards LA antibodies in plasma (43).
Our findings indicate that the interaction between antiphospholipid
antibodies and anionic phospholipids is mediated by plasma proteins and that
at least three different types of antibodies can be recognized. Thus, two
acquired inhibitors of blood coagulation - aCL-type A and LA antibodies -
exist among antiphospholipid antibodies that interfere with phospholipid-
dependent coagulation reactions. In contrast, aCL-type B antibodies are only
detectable by solid phase immunoassay. The reason why this antibody,
although B2-GPI dependent, is unable to interfere with lipid-dependent
coagulation reactions is presently unknown. In the majority of the cases LA
and aCL-type A antibodies can easily be distinguished, apparently because
most LA antibodies exert their action only in human plasma, whereas aCL-
type A antibodies inhibit coagulation reactions in a strictly l^-GPI-dependent
way irrespective of the plasma source. The species specificity of some LA
antibodies, however, is not restricted to human prothrombin only, but might
be extended to prothrombin of other species as well.
The existence among antiphospholipid antibodies of two different
inhibitors of coagulation, both affecting phospholipid-dependent coagulation
tests, may produce difficulties in the interpretation of the published data. In
fact, until now the term LA has been indiscriminately used to refer to all cases
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of non-specific, phospholipid-dependent inhibitors of coagulation. For
instance, Oosting and coworkers described a LA activity, which actually has
the properties of aCL-type A antibodies (34). Similarly, Janoff et al. used the
term LA activity to refer to an anticoagulant activity that is neutralized by
hexagonal (HJJ) PE (19). Since the same authors described the ability of 82-
GPI to induce hexagonal (HJJ) phase phospholipids (16), one might argue that
they were also dealing with aCL-type A antibodies.
The use of a new nomenclature for antiphospholipid antibodies may be helpful
to overcome the existent confusion. In this respect, we here suggest to adopt
the term "Anti lipid-bound protein antibodies".
Our observation that 62-GPI and prothrombin are involved in the
expression of the immunological activity of antiphospholipid antibodies led us
to propose a new hypothetical model for the generation of these antibodies in
the antiphospholipid syndrome (44). As shown in Fig. 2, a persistent
endothelial cell damage and/or platelet activation causes increased expression
of procoagulant (read: anionic phospholipid) surfaces.
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Proteins such as 62-GPI and prothrombin, which have a high affinity for
anionic phospholipids and are relatively abundant in plasma (about 4 umol/1
and 2.5 (i.mol/1, respectively), may bind to these surfaces, thus exposing
cryptic epitopes. The immune response, therefore, could be addressed to the
modified proteins rather than to the lipids and should be regarded as a
consequence of the exposure of neo-autoantigens instead of being caused by a
disregulation of the immune system.
This hypothesis offers an explanation for the frequently observed concurrence
of aCL and LA antibodies in the antiphospholipid syndrome and it does not
exclude the possibility that the 62-GPI-independent binding of some aCL
antibodies generally observed in infectious diseases could involve other, as yet
unidentified, protein cofactors. Moreover, it also implays a possible
explanation for the correlation between antiphospholipid antibodies and
thrombosis, since the presence of circulating procoagulant surfaces (such as,
for instance, platelet-derived microvesicles) has been suggested to represent a
prothrombotic condition (45).
Finally, in view of the involvment of 62-GPI and prothrombin, it
becomes necessary to re-evaluate the question whether antiphospholipid
antibodies play a part - if any - in the pathogensis of thrombosis. Moreover, it
is also conceivable that antibodies directed to other protein "cofactors", known
to bind to anionic phospholipid surfaces, will be identified. The recent
observation by Oosting and coworkers of antibodies that bind the lipid-
bound/activated protein C complex (46) supports our hypothesis. These and,
possibly, other "anti-lipid bound protein antibodies", more than LA and aCL
antibodies, might be responsible for the thromboembolic complications
associated with the antiphospholipid syndrome.
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CHAPTER VII
SUMMARY AND CONCLUSIONS
Antiphospholipid antibodies represent a wide group of autoantibodies,
which includes anticardiolipin (aCL) and lupus anticoagulant (LA) antibodies.
aCL antibodies bind to anionic phospholipids in the immunoassays, whereas
LA antibodies prolong phospholipid-dependent coagulation tests. They are
associated with an increased risk of arterial and/or venous thromboembolism,
repeated abortions and thrombocytopenia. The disorder characterized by the
presence of these antibodies has been named "Antiphospholipid syndrome".
aCL and LA antibodies occur concurrently in 75% of the cases and have,
therefore, been considered closely related or even identical, based on the
ability of some affinity-purified aCL antibodies to prolong phospholipid-
dependent coagulation assays. In recent years, however, it has been
demonstrated that in most cases aCL antibodies can be separated from LA
antibodies. It has also become clear that the interaction between
antiphospholipid antibodies and their putative antigens is far more complex
than previously thought and that this interaction requires the participation of
protein "cofactors".
./?2-<j/;yco/?ro/em /: co/actor m f/ie 6/nrfing o/aCL
Cofactor involvement in the binding of aCL antibodies to negatively-
charged phospholipids is pointed out by the observation that isolated aCL
antibodies are able to bind to anionic phospholipid-containing liposomes and to
negatively-charged phospholipids coated ELISA plates only in the presence of
human (bovine) plasma (serum). The cofactor of aCL antibodies has been
purified and characterized as a single chain polypeptide with an apparent
molecular weight of 50 kD (non-reduced), which increases to 70 kD upon
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reduction; it has an approximate concentration in plasma of 4 junol/l (0.2
mg/ml); it is heat-stable (10 min at 90 °C does not reduce its cofactor capacity)
and can bind to anionic phospholipids also in the absence of aCL antibodies.
This protein has been identified as B2-Glycoprotein I (B2-GPI, also referred to
as apolipoprotein H). Due to its interaction with negatively-charged surfaces,
62-GPI has been shown to have several anticoagulant properties "in vitro",
among which is the inhibition of the conversion of prothrombin by
coagulation factors Xa/Va in presence of phosphatidylserine/
phosphatidylcholine (PS/PC) vesicles. The inhibition is maximal at
physiological concentrations of the protein and requires prolonged incubation
with the phospholipid surface (approximately 60 min are necessary to express
maximal inhibition).
Affinity-purified aCL antibodies have been observed to display 2
different behaviours in coagulation tests: aCL-type A antibodies prolong
phospholipid-dependent coagulation reactions in plasma of human as well as
animal origin, whereas aCL-type B antibodies are devoid of anticoagulant
effect. The inhibitory effect of aCL-type A antibodies is strictly 62-GPI
dependent, since it is abolished in human plasma depleted of B2-GPI and can
be restored upon addition of the protein. The anticoagulant mechanism of
aCL-type A antibodies is due to the potentiation of the B2-GPI effect on the
conversion of prothrombin by factors Xa/Va on PS/PC vesicles (85%
inhibition within 10 min).
It is important to emphasize that only a minority (approximately 1/3) of aCL
antibodies preparations express anticoagulant activity. In the other cases the
inhibitory effect observed in plasma containing antiphospholipid antibodies is
due to LA antibodies.
Isolated LA antibodies, separated from aCL antibody preparations, do
not bind directly to anionic phospholipids in ELISA assays, neither can be
removed from plasma by adsorption to cardiolipin-containing liposomes.
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Moreover, most LA antibodies are able to prolong the coagulation times of
phospholipid-dependent coagulation tests (such as aPTT, KCT and dRVVT)
only in presence of human plasma; no prolongation of the coagulation times
can generally be seen when plasma of bovine, sheep or rat origine is used. The
prolongation of the dR W T also indicates that LA antibodies act at the level of
conversion of prothrombin to thrombin by coagulation factors Xa/Va on a
phospholipid surface. In a system using purified coagulation factors (Xa, Va
and prothrombin) of human and bovine origin in the presence and absence of
PS/PC vesicles, LA antibodies do not produce appreciable inhibition on the
rate of conversion of bovine prothrombin. The inhibitory effect observed in
the presence of human prothrombin is independent of the source of factors Xa
and Va and is not found in the absence of lipids. Moreover, LA antibodies bind
to anionic phospholipids only when human prothrombin and calcium ions are
present. Therefore, these LA antibodies most likely recognize an epitope
which becomes exposed upon calcium-mediated binding of human
prothrombin to anionic phospholipids. This species-specificity, however, does
not seem to be absolute, since we have been able to characterize one
preparation of LA antibodies, which can recognize lipid-bound prothrombin
of both human and animal origin.
ief; z'nrerac/ion w/r/i p/are/e/s and p/afe/er
In vivo, the catalytic surface for the formation of the prothrombin (and
also factor X) activating complex is thought to be provided by the
phospholipids of the platelet plasma membrane. However, anionic
phospholipids, which are essential to the catalytic properties of the surface, are
located in the inner leaflet of the membrane of resting platelets. Dependent on
the agonist used, platelet activation leads to a loss of phospholipid asymmetry,
resulting in the formation of a procoagulant surface and to shedding of
procoagulant microvesicles. Our studies on the effects of LA and aCL-type A
and B antibodies on the procoagulant activity of activated platelets and
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platelet-derived microvesicles have been performed in the presence and
absence of B2-GPI, using purified coagulation factors of both human and
bovine origin. In presence of their respective cofactors, LA antibodies and
aCL-type A but not type B antibodies interact with the membrane of activated
platelets and platelet-derived microvesicles in a way very similar to that
observed for their interaction with PS/PC vesicles. The inhibition of
procoagulant activity is proportional to the amount of anionic phospholipid
(PS) exposed on the surface.
In conclusion, we have demonstrated that the interaction between
antiphospholipid antibodies and anionic phospholipids is mediated by plasma
proteins and that at least 3 different types of these antibodies (LA, aCL-type A
and B) can be recognized, which express different immunological and
anticoagulant properties. In view of these new findings it will be necessary to
re-evaluate the role that antiphospholipid antibodies might play with respect to
the pathogenesis of thromboembolic complications frequently occurring in
patients who suffer from the antiphospholipid syndrome.
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CAPITOLO VI
SOMMARIO E CONCLUSIONI
Gli anticorpi antifosfolipidi rappresentano un ampio gruppo di
autoanticorpi, che comprendono gli anticorpi anticardiolipina (aCL) e 1'
anticoagulante tipo lupus (LA). Gli anticorpi aCL si legano ai fosfolipidi
anionici nei tests immunoenzimatici, mentre gli anticorpi LA inibiscono Ie
reazioni di coagulazione fosfolipide-dipendenti. Sono associati ad un rischio
elevato di trombosi venosa e/o arteriosa, poliabortivita e piastrinopenia e la
loro presenza definisce la "Sindrome da anticorpi antifosfolipidi". Gli
anticorpi aCL e LA sono stati a lungo considerati strettamente correlati e
perfino identici, poiché si osservano contemporaneamente in circa il 75% dei
casi e poiché alcuni anticorpi aCL purificati per affinita sono in grado di
prolungare i tests della coagulazione fosfolipide-dipendenti. Recentemente,
tuttavia, è stato dimostrato che gli anticorpi aCL possono essere separati dagli
anticorpi LA nella maggior parte dei casi. Inoltre, 1' interazione tra gli
anticorpi antifosfolipidi e i loro bersagli antigenici si è rivelata piü complessa
di quanto in precedenza ipotizzato, richiedendo la partecipazione di "cofattori"
proteici.
^ /: co/ia«ore deg/i'
La necessita di un cofattore per il legame degli anticorpi aCL ai
fosfolipidi a carica negativa è evidenziata dall' osservazione che gli anticorpi
aCL purificati per affinita sono capaci di legarsi ai fosfolipidi anionici
contenuti nei liposomi o adsorbiti sulle piastre ELISA solo in presenza di
plasma (o siero) umano (o bovino). Il cofattore degli anticorpi aCL è stato
isolato e caratterizzato come una proteina a singola catena, con peso
molecolare di 50 kD (in condizioni non ridotte), che sale a 70 kD dopo
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riduzione; ha una concentrazione plasmatica di circa 4 umol/l (0,2 mg/ml); è
stabile al calore (la sua attivita cofattore non è alterata dopoiO min a 90 °C) e
puö legarsi ai fosfolipidi anionici anche in assenza degli anticorpi aCL. La
proteina è stata identificata come 62-Glicoproteina I (B2-GPI, anche nota come
apolipoproteina H). A causa della sua interazione con Ie superfici a carica netta
negativa, la 82-GPI possiede numerose proprieta anticoagulanti "in vitro", tra
cui c' è la capacita di inibire la conversione della protrombina da parte del
complesso protrombinasico (costituito dai fattori della coagulazione Xa e Va in
presenza di vescicole di fosfatidilserina/fosfatidilcolina, PS/PC). L' inibizione
massimale si ottiene a concentrazioni fisiologiche di 62-GPI e richiede
incubazioni prolungate (circa 60 min) con la superficie fosfolipidica.
Gli anticorpi aCL purificati per affinita esprimono due diversi
comportamenti nei tests della coagulazione: gli aCL-tipo A prolungano i tests
fosfolipide-dipendenti in plasma di origine sia umana, sia animale, mentre gli
aCL-tipo B non possiedono attivita anticoagulante. L' effetto inibitorio degli
aCL-tipo A dipende strettamente dalla presenza della B2-GPI: è, infatti,
abolito nel plasma depleto di B2-GPI ed è nuovamente evidente in seguito al
ripristino dell' originale concentrazione plasmatica della proteina. Il
meccanismo anticoagulante degli aCL-tipo A è dovuto al potenziamento dell'
effetto inibitorio esercitato dalla B2-GPI sulla conversione della protrombina
da parte del complesso protrombinasico (85% di inibizione entro 10 min).
E' importante sottolineare che soltanto una minoranza (circa 1/3) degli
anticorpi aCL esprimono attivita anticoagulante. Negli aïtri casi 1' effetto
inibitorio che si osserva nel plasma contenente anticorpi antifosfolipidi è
dovuto alia presenza degli anticorpi LA.
Gli anticorpi LA isolati e separati dagli aCL non si legano direttamente
ai fosfolipidi anionici nei tests immunoenzimatici e non vengono adsorbiti in
seguito ad incubazione del plasma con liposomi contenenti cardiolipina.
Inoltre, la maggior parte degli anticorpi LA è in grado di inibire i tests della
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coagulazione fosfolipide-dipendenti (quali 1' aPTT, il KCT e il dRVVT) in
presenza di plasma umano ma non di quello di origine animale. L' inibizione
del dRVVT indica anche che gli anticorpi LA esprimono il loro effetto
anticoagulante a livello della conversione della protrombina da parte del
complesso protrombinasico. In un sistema contenente fattori purificati della
coagulazione (Xa, Va e protrombina) di origine umana e bovina gli anticorpi
LA non sono in grado di inibire la conversione della protrombina bovina. L'
effetto inibitorio osservato in presenza di protrombina umana è indipendente
dall' origine dei fattori Xa e Va e si esprime solo in presenza di vescicole di
PS/PC. Inoltre, gli anticorpi LA si legano ai fosfolipidi anionici solo se quest'
ultimi sono preincubati con la protrombina e gli ioni calcio. Perciö, è assai
probabile che gli anticorpi LA riconoscano un epitopo esposto in seguito al
legame della protrombina umana ai fosfolipidi anionici. Questa specie-
specificita non è, perö, assoluta, poichè è stata isolata e caratterizzata anche
una preparazione di anticorpi LA che riconoscono il complesso fosfolipide
anionico/protrombina di origine sia umana, sia animale.
i': /nrerazione con /e piattr/m e /e
La membrana delle piastriniche è considerata rappresentare la superficie
che catalizza "in vivo" la formazione del complesso attivatore della
protrombina (e del fattore X). Tuttavia, i fosfolipdi anionici essenziali per 1'
espressione delle proprieta procoagulanti delle piastrine sono localizzati
principalmente nella superficie interna della membrana e non sono, perciö,
disponibili per i processi di coagulazione. Questa distribuzione asimmetrica
dei fosfolipidi viene meno in seguito all' attivazione piastrinica, cui
conseguono la formazione di una superficie procoagulante e lo "shedding" di
microvescicole piastriniche, anch' esse dotate di proprieta procoagulante. I
nostri studi sull' effetto degli anticorpi LA e aCL sull' attivita procoagulante
delle piastrine e delle microvescicole sono stati condotti in presenza e in
assenza di B2-GPI, usando fattori purificati della coagulazione di origine
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umana e bovina. In presenza dei rispettivi cofattori gli anticorpi LA e aCL-
tipo A, ma non tipo B, interagiscono con la membrana delle piastrine attivate e
delle microvescicole di denvazione piastnnica in maniera sovrapponibile a
quanto gia osservato con le vescicole di PS/PC. In particolare, 1' inibizione
dell' attivita procoagulante è risultata proporzionale alia quantita di fosfolipide
anionico (PS) esposto sulla superficie procoagulante.
In conclusione, abbiamo dimostrato che 1' interazione tra gli anticorpi
antifosfolipidi e i fosfolipidi anionici è mediata da proteine plasmatiche e che
esistono almeno 3 tipi di anticorpi (LA, aCL-tipo A e tipo B), che possiedono
diverse proprietè immunologiche ed anticoagulanti. Alia luce di queste nuove
osservazioni diventa importante rivalutare il ruolo che questi anticorpi
potrebbero svolgere nella patogenesi delle trombosi nell' ambito della
sindrome da anticorpi antifosfolipidi.
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HOOFDSTUK VII
SAMENVATTING EN CONCLUSIES
Antifbsfolipiden antilichamen vertegenwoordigen een grote groep van
antistoffen waaronder anticardiolipine (aCL) en lupus anticoagulant (LA).
aCL antilichamen binden aan negatief-geladen lipiden in immunoassays
(ELISA), terwijl LA antilichamen de stoltijd van lipid-afhankelijke stoltesten
verlengen. Beide antistoffen zijn geassocieerd met een verhoogd risiko voor
arteriele en/of veneuze tromboembolische complicaties, spontane abortus en
trombocytopenie. Het ziektebeeld dat door aanwezigheid van deze antistoffen
wordt gekarakteriseerd, wordt aangeduid als het "Antifosfolipiden syndroom".
Omdat aCL en LA antilichamen gemeenschappelijk voorkomen in 75% van de
gevallen en omdat sommige affiniteits-gezuiverde aCL antilichamen lipid-
afhankelijke stolreakties remmen, zijn deze beide antilichamen lange tijd als
identiek beschouwd. In de afgelopen jaren echter, is aangetoond dat in de
meerderheid van de gevallen aCL antilichamen kunnen worden gescheiden van
LA antilichamen. Bovendien werd duidelijk dat de interaktie tussen
antifosfolipid antilichamen en hun veronderstelde antigenen aanzienlijk
complexer is dan voorheen werd aangenomen en dat deze interaktie via eiwit
"cofactoren" plaatsvindt.
^ n /: co/ïicfor voor rfe biruftng van aCL an/zï/c/iamen
Aanwijzing voor de noodzaak van een cofactor voor de binding van
aCL antistoffen aan negatief-geladen fosfolipiden kwam door de observatie dat
geïsoleerde aCL antilichamen uitsluitend in aanwezigheid van humaan (of
runder) plasma (of serum) in staat waren te binden aan liposomen bestaande
uit negatief-geladen lipid of aan ELISA platen gecoat met deze lipiden. Deze
"aCL-cofactor" werd gezuiverd en gekarakteriseerd als een enkelvoudige
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polypeptideketen met een schijnbare molecuulmassa van 50kD (niet-
gereduceerd), toenemend tot 70 kD na reduktie; de concentratie van dit eiwit
in plasma bedraagt ongeveer 4 umol/1 (0,2 mg/ml); het eiwit is hittestabiel (10
minuten verhitting op 90 °C geeft geen afname in cofactor aktiviteit) en bindt
aan anionische fosfolipiden, ook in afwezigheid van aCL antilichamen. Het
eiwit werd geïdentificeerd als 82-glycoprotein I (82-GPI, ook wel aangeduid
als apolipoprotein H). Aangetoond werd dat ten gevolge van zijn interaktie
met negatief-geladen oppervlakken, 62-GPI "in vitro" verschillende
anticoagulante eigenschappen vertoont, waaronder het vermogen de aktivering
van prothrombine door het enzymcomplex factor Xa-Va in aanwezigheid van
fosfatidylserine/fosfatidylcholine (PS/PC) vesicles te remmen. Deze remming
is maximaal bij fysiologische concentraties van het eiwit en vereist langdurige
incubatie met het fosfolipiden oppervlak (ongeveer 60 minuten zijn nodig
voor maximale expressie van de remming).
Op grond van hun gedrag in stoltesten kunnen aCL antilichamen worden
ingedeeld in twee verschillende groepen: aCL-type A antilichamen verlengen
de stoltijd van lipid-afhankelijke stolreakties in plasma van zowel humane als
dierlijke oorsprong, terwijl aCL-type B antilichamen geen anticoagulante
werking vertonen. De remmende werking van aCL-type A is strikt afhankelijk
van de aanwezigheid van B2-GPI, hetgeen blijkt uit het feit dat de verlengde
stoltijden normalizeren bij verwijdering van B2-GPI uit het plasma; toevoegen
van B2-GPI-deficient plasma geeft weer aanleiding tot verlenging van de
stoltijden door dit type antilichamen. De anticoagulante eigenschappen van
aCL-type A worden verklaard door potentiering van de B2-GPI remming op
de omzetting van prothrombine door het complex van de factoren Xa en Va op
PS/PC vesicles (85% remming in 10 minuten). Het is van belang te
onderstrepen dat van de aCL preparaten slechts een gering deel (ongeveer 1/3)
deze anticoagulante eigenschappen vertoont. In de andere gevallen wordt de
anticoagulante aktiviteit van het plasma verklaard door aanwezigheid van LA
antilichamen.
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pror/iromo/ne: co/acror voor de o/nd/ng van LA
Geïsoleerde LA antilichamen, gescheiden van aCL antilichamen, binden
niet rechtstreeks aan anionische fosfolipiden in de ELISA, noch kunnen deze
antistoffen uit het plasma worden verwijderd door middel van adsorptie aan
cardiolipine-bevattende liposomen. Bovendien blijken de meeste LA
antilichamen uitsluitend in humaan plasma een verlenging te veroorzaken van
de stoltijden van lipid-afhankelijke stoltesten (zoals bijvoorbeeld aPTT, KCT
en dRVVT); toegevoegd aan runder-, schape-, of ratte-plasma vertonen deze
gezuiverde LA antistoffen geen anticoagulante werking. Verlenging van de
dRVVT wijst er op dat LA antistoffen werkzaam zijn op het niveau van de
omzetting van prothrombine naar thrombine door factoren Xa/Va op een
lipiden oppervlak. In een meetsysteem gebruik makend van zuivere
stolfactoren (Xa, Va en prothrombine) van humane of runder oorsprong
wordt, noch in aan- noch in afwezigheid van PS/PC vesicles, een significante
remming waargenomen op de omzettingssnelheid van runder-prothrombine.
Remming wordt uitsluitend waargenomen op de omzettingssnelheid van
humaan prothrombine en is onafankelijk van de oorsprong van de factoren Xa
en Va. Bovendien wordt de remming niet waargenomen in afwezigheid van
lipid. Tevens kon worden aangetoond dat LA antilichamen alleen in
aanwezigheid van humaan prothrombine en calcium-ionen aan anionische
fosfolipiden kunnen binden. Het meest waarschijnlijke is daarom dat deze LA
antilichamen een epitoop herkennen dat geëxposeerd wordt als gevolg van de
calcium-gemedieerde binding van humaan prothrombine aan negatief-geladen
fosfolipiden oppervlakken. Deze soort-specificiteit lijkt evenwel niet absoluut
te zijn; tenmiste één LA antilichaam preparaat bleek lipid-gebonden
prothrombine te herkennen van zowel mens als rund.
a/i//7/c/iamen: /nrerait/ze me/ o/oea/j/aaf/e.r en daarvan
q/ge/eide mfcr0ve.Hc/e.ï.'
Het katalytisch oppervlak voor de vorming van het prothrombine-
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aktiverende complex (en ook het faktor X-aktiverende complex) "in vivo"
wordt naar alle waarschijnlijkheid geleverd door de fosfolipiden in het
plasmamembraan van de bloedplaatjes. De voor de katalytische eigenschappen
van het oppervlak verantwoordelijke lipiden bevinden zich in het niet
geaktiveerde bloedplaatje echter aan de cytoplasmatische zijde van de
plasmamembraan. Afhankelijk van de agonist leidt aktivatie van bloedplaatjes
tot een verlies van deze asymmetrische fosfolipidenverdeling, hetgeen
resulteert in de vorming van een procoagulant fosfolipidenoppervlak en tevens
het afsnoeren van procoagulante microvesicles. Onze studies betreffende de
effecten van LA en aCL-type A en B antilichamen op de procoagulante
aktiviteit van geaktiveerde plaatjes en microvesicles werden uitgevoerd in aan-
en afwezigheid van B2-GPI, opnieuw gebruikmakend van gezuiverde
stollingsfactoren van humane- en runder oorsprong. In aanwezigheid van hun
respectivelijke cofactoren blijken LA en aCL-type A de procoagulante
aktiviteit van geaktiveerde plaatjes en plaatjesmicrovesicles op een soortgelijke
manier te remmen als hierboven beschreven voor PS/PC vesicles, terwijl de
aCL-type B antilichamen ook hier geen anticoagulante werking vertoonden.
De mate van remming van procoagulant aktiviteit is evenredig met de
hoeveelheid anionisch fosfolipid (PS) geëxposeerd aan het celoppervlak.
Concluderend kan gesteld worden dat de interaktie tussen
antifosfolipiden antilichamen en anionische fosfolipiden wordt gemedieerd
door plasma eiwitten en dat er tenmiste drie verschillende typen antilichamen
(LA, aCL-type A en B) kunnen worden onderscheiden, met elk verschillende
immunologische en anticoagulante eigenschappen. In het licht van deze
bevindingen zal een re-evaluatie noodzakelijk zijn van de rol van
antifosfolipiden antilichamen in de pathogenese van tromboembolische
complicaties, die zo veelvuldig voorkomen bij patiënten met het
antifosfolipiden syndroom.
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